Compositions for the transtympanic delivery of antibiotics and methods for using the same

A composition combining a therapeutic compound with a fatty acid methyl ester and hydrophilic non-ionic surfactant enhances antibiotic delivery across the tympanic membrane, addressing the inefficiencies of current methods and providing effective, non-invasive treatment for otitis media by forming a stable pseudo-surfactant assembly within a hydrogel.

WO2024233921A1PCT designated stage expired Publication Date: 2024-11-14CORNELL UNIVERSITY +1
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
PCT/US2024/028845
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-10
Filing Date
2024-05-10
Publication Date
2024-11-14

AI Technical Summary

Technical Problem

Current methods for delivering antibiotics across biological barriers, such as the tympanic membrane, face challenges due to interference from ionic surfactants, which disrupt hydrogel stability and therapeutic agent diffusion, leading to inefficient and invasive treatment options for otitis media.

Method used

A composition comprising a therapeutic compound, a fatty acid methyl ester as a permeation enhancer, and a hydrophilic non-ionic surfactant, forming a pseudo-surfactant assembly that interacts with a hydrogel precursor to enhance transmembrane delivery without disrupting hydrogel stability, allowing for non-invasive administration of antibiotics like ciprofloxacin.

Benefits of technology

The composition achieves enhanced permeation and bioavailability of antibiotics across the tympanic membrane, effectively treating otitis media without the need for invasive procedures or prolonged treatment periods, while maintaining hydrogel stability and reducing cytotoxicity.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure IMGF000006_0001
    Figure IMGF000006_0001
  • Figure IMGF000019_0001
    Figure IMGF000019_0001
  • Figure IMGF000022_0001
    Figure IMGF000022_0001
Patent Text Reader

Abstract

The present invention relates to compositions suitable for the transdermal, transmembrane, transmucosal, and / or transtympanic administration of a therapeutically effective amount of a therapeutic compound such as an antibiotic for treating a subject, wherein the delivery of the therapeutic compound is enhanced by forming a pseudo- surfactant assembly with a first compound comprising a chemical penetration enhancer.
Need to check novelty before this filing date? Find Prior Art

Description

COMPOSITIONS FOR THE TRANSTYMPANIC DELIVERY OF ANTIBIOTICS AND METHODS FOR USING THE SAME

[0001] This invention was made with government support under Grant No. R21DC019184-01A1 from the National Institutes of Health. The U.S. government has certain rights in the invention.CROSS-REFERENCE TO RELATED APPLICATIONS

[0002] This application claims priority to U.S. Provisional Application No. 63 / 465,465, filed May 10, 2023, the entire disclosure of which is hereby incorporated by reference.FIELD OF THE INVENTION

[0003] The present invention relates to compositions suitable for the transdermal, transmembrane, transmucosal, and / or transtympanic administration of a therapeutically effective amount of a therapeutic compound such as an antibiotic for treating a subject. In some embodiments, the compositions of the present invention are stable hydrogels.BACKGROUND OF THE INVENTION

[0004] To date, over 600 chemical permeation enhancers have been discovered, many of which are FDA-approved for use in human drug products for transdermal, transbuccal, and / or intestinal drug delivery (see Refs. 1-4). Chemical permeation enhancers are broadly categorized as solvents (e.g., water, dimethylsulphoxide, pyrrolidones), surfactants, terpenes, azones, fatty acids, urea, phospholipids, etc. (see Ref 5). For transdermal drug delivery, chemical permeation enhancers predominantly act on the intercellular lipid matrix, disrupting the tightly packed crystalline lipid bilayers and creating defects to enable the permeation of therapeutics.

[0005] Despite the wide variety of existing chemical permeation enhancers, there is a need for new molecular design strategies to meet the evolving needs in drug delivery across biological barriers. For example, to achieve sustained drug delivery across biological barriers, chemical permeation enhancers and therapeutics are often co-administered in a temperature- responsive hydrogel, such as those made of poloxamer 407 (P407) in water. However, certain small-molecule chemical permeation enhancers, such as ionic surfactants, are known to interfere strongly with the micellization of the hydrogel components, which can lead to undesirable effects including an inability of the composition to maintain a stable gel (see Refs 6-9).

[0006] Ionic surfactants such as sodium dodecyl sulfate (SDS) can also interact with the therapeutic agents such as ciprofloxacin (see Refs 10-11), resulting in aggregate that cannotdiffuse through a hydrogel or do so very slowly (see Refs 12-14). As ionic surfactants make up a significant class of commonly chemical permeation enhancers (for example, sodium alkyl sulfates and quaternary alkyl ammonium salts (see Refs 1, 3, and 15), surfactant-drug- hydrogel interactions present a significant challenge in the development of hydrogel compositions for drug delivery.

[0007] The current standard of care for otitis media is a non-local, oral antibiotic course (Refs. 16-18), which is undesirable due to: (1) the need for a multi-day, multidose administration, (2) the resulting systemic exposure (Ref. 19), and (3) the high risk of antibiotic resistance due to patient non-compliance or frequent antibiotic use to treat recurring infections (Refs. 20-22). Local otitis media treatment options exist, as there are currently a limited number of FDA- approved otic drops, e.g. Ciprodex® (0.3% ciprofloxacin, 0.1% dexamethasone) (Refs. 27-28) and Cetraxal® (0.2% ciprofloxacin) (Ref. 29). Unfortunately, these products are usually limited to patients with a surgically placed tympanostomy tube, and require an extended treatment period of 7 to 14 days (Refs. 43, 68). Similarly, Otiprio® is an FDA-approved solution of 6% ciprofloxacin in P407 for sustained drug release, but it is also limited to patients with tympanostomy tube or requires an invasive intra-tympanic injection (Refs. 43, 66, 69).

[0008] Non-invasive delivery across the tympanic membrane is difficult as the membrane has low permeability to all but small, moderately hydrophobic compounds (see Refs. 24-26).

[0009] While that challenge might be addressed by designing new polymers that minimize interactions with surfactants and / or therapeutic compounds, such development would also require regulatory approval in order to be used in clinical practice.

[0010] What is needed are new compositions capable of administering therapeutic compounds across biological barriers using known compounds that do not require further regulatory approval.BRIEF SUMMARY OF THE INVENTION

[0011] The present invention is directed to compositions suitable for administration of a therapeutic compound across a biological barrier. In some embodiments, the present invention is directed to a composition to facilitate transtympanic delivery of a therapeutic compound comprising the therapeutic compound, a first compound comprising a permeation enhancer that comprises a fatty acid methyl ester having a Cio to C20 n-alkyl or branched alkyl chain, and a second compound comprising a hydrophilic non-ionic surfactant; wherein the therapeutic compound has a molecular weight of about 200 g / mol to about 1,000 g / moland is at least one of: ionized at pH 3 to 8, contains a Hydrogen-bond donor functional group; contains a Hydrogen-bond acceptor functional group, or a combination thereof.

[0012] In some embodiments, the present invention is directed to a composition for delivering a therapeutic compound to a patient comprising: a therapeutic compound having a molecular weight of about 200 g / mol to about 1,000 g / mol that is at least one of:(i) ionized at pH 3 to 8;(ii) contains a Hydrogen-bond donor functional group;(iii) contains a Hydrogen-bond acceptor functional group; or(iv) a combination thereof, a first compound comprising one or more ester groups and one or more optionally substituted Cio to C20 chains, wherein the first compound and therapeutic compound interact form a pseudo-surfactant assembly; a second compound comprising a non-ionic surfactant or a hydrogel precursor that forms a micelle, liposome, or vesicle with water, wherein the pseudo-surfactant assembly is incorporated into the micelle, liposome, or vesicle, and wherein the composition has a pH of 3 to 8.

[0013] In some embodiments, the present invention is directed to a composition comprising: a therapeutic compound having a molecular weight of about 200 g / mol to about 1,000 g / mol that is:(i) ionized at pH 3 to 8;(ii) contains a Hydrogen-bond donor functional group;(iii) contains a Hydrogen-bond acceptor functional group; or(iv) a combination thereof; a first compound comprising a fatty acid methyl ester having a Cio to C20 n-alkyl or branched alkyl chain; a second compound comprising a hydrophilic non-ionic surfactant; and water, wherein the composition has a pH of 3 to 8.

[0014] Most broadly, the compositions of the present invention are suitable for administering therapeutic compounds having a molecular weight of about 200 g / mol to about 1,000 g / mol and that are at least one of: anionic, cationic, include a Hydrogen-bond donor functional group, include a Hydrogen-bond acceptor functional group, or a combination thereof.

[0015] In some embodiments, the therapeutic compound is selected from a quinolone antibiotic, a tetracycline antibiotic, a macrolide antibiotic, an aminoglycoside, a steroid, derivatives thereof, or a combination thereof. In some embodiments, the therapeutic compound has a solubility of less than 0.1 g / L in water at 20 °C.

[0016] In some embodiments, the therapeutic compound is a quinolone antibiotic or a salt thereof. In some embodiments, the therapeutic compound is a quinolone antibiotic selected from: ciprofloxacin, garenoxacin, gatifloxacin, gemifloxacin, levofloxacin, moxifloxacin, salts thereof, and combinations thereof. In some embodiments, the therapeutic compound is ciprofloxacin.

[0017] In some embodiments, the therapeutic compound is present in a concentration of about 0.1% w / v to about 10% w / v, preferably about 1% w / v to about 8% w / v, or more preferably about 2% w / v to about 6% w / v.

[0018] In some embodiments, the compositions of the present invention further comprise one or more additional therapeutic compounds. Additional therapeutic compounds suitable for use with the present invention include analgesics such as bupivacaine, lidocaine, tetracaine, benzocaine, and prilocaine.

[0019] In some embodiments, the therapeutic compound and first compound are present in the compositions of the present invention at a molar ratio of about 1:2 to about 2:1, or about 1:1.

[0020] In some embodiments, the first compound is selected from an ester, a diester, or an oligo-ester comprising a Ce to C20 carbon chain. In some embodiments, the first compound is a C<> to C20 fatty acid ester. In some embodiments, the first compound is a fatty acid ester having a Ce to C20 n-alkyl or branched alkyl chain and a methyl, ethyl, propyl, isopropyl, or butyl ester group, or preferably a fatty acid ester having a Ce to Cis n-alkyl or branched alkyl chain and a methyl, ethyl, propyl, isopropyl, or butyl ester group.

[0021] In some embodiments, the first compound is a Ce to C20 fatty acid methyl ester. In some embodiments, the first compound consists essentially of a fatty acid methyl ester having a C<> to C20 n-alkyl or branched alkyl chain. In some embodiment, the fatty acid methyl ester comprises methyl laurate. In some embodiments, the permeation enhancer consists essentially of methyl laurate.

[0022] In some embodiments, the first compound comprises a fatty acid methyl ester present in a concentration of about 0.5% w / v to about 5% w / v, more preferably about 1% w / v to about 4% w / v, and most preferably about 2% w / v.

[0023] In some embodiments, the therapeutic compound comprising a Hydrogen-bound donor functional group, a Hydrogen-bond acceptor functional group, or a combination thereof; and the first compound comprises a Hydrogen-bond acceptor functional group, a Hydrogen-bond acceptor functional group, or a combination thereof, and the therapeutic compound and first compound interact via one or more Hydrogen-bonds to form a pseudosurfactant assembly.

[0024] In some embodiments, the pseudo-surfactant assembly formed by the therapeutic compound and first compound further interacts with the second compound to form a micelle assembly, a hydrogel, or a combination thereof.

[0025] In some embodiments, the second compound comprises a hydrophilic non-ionic surfactant having the structure of formula I:wherein a is independently an integer of about 50 to about 150, preferably about 75 to about 125, and most preferably about 100; and b is independently an integer of about 40 to about 70, and preferably about 50 to about 60, and most preferably about 55. In some embodiments, a is an integer of about 50 to about 150 and b is an integer of about 40 to 70, preferably a is an integer of about 75 to about 125 and b is an integer of about 50 to about 60, and more preferably a is an integer of 100 and b is an integer of 55.

[0026] In some embodiments, the second compound is a non-ionic surfactant or a neutral surfactant. In some embodiments, the second compound is selected from a poloxamer or a derivative thereof, a reverse poloxamer or a derivative thereof, a polyethylene glycol polymer, and a combination thereof. In some embodiments, the second compound is selected from a polysorbate, sodium lauryl sulfate, poloxamer, polyoxyl 40 hydrogenated castor oil, lauroyl polyoxyl-32 glycerides, mannide monooleate, propylene glycol monocaprylate, and a combination thereof. In some embodiments, the second compound is selected from P407, P188, P338, MAKON 17R2, MAKON 17R4, poloxamer / pluronic diacrylate, poloxamer dimethacrylate, PEGDA, PEGMA, PLGA-PEG-PLGA, PEG-PCL-PEG, and a combination thereof.

[0027] In some embodiments, the second compound is a thermoresponsive polymer, a thermoresponsive block copolymer, or a combination thereof.

[0028] In some embodiments, the composition is thermosensitive with a transition from a liquid at a first temperature to a hydrogel at a second temperature. In some embodiments, thecompositions of the present invention form a stable hydrogel at a temperature of about 20 °C to about 40 °C. In some embodiments, the compositions of the present invention have a solgel transition temperature at about 4 °C to about 35 °C.

[0029] In some embodiments, the second compound comprises a hydrophilic non-ionic surfactant is present in a concentration of about 10% w / v to about 25% w / v, or more preferably about 15% w / v to about 25% w / v.

[0030] In some embodiments, the first compound is methyl laurate in a concentration of about 1% w / v to about 4% w / v, and the second compound is a hydrophilic non-ionic surfactant in a concentration of about 15% w / v to about 25% w / v.

[0031] In some embodiments, the compositions of the present invention comprise the therapeutic compound in a concentration of 0.005% w / v to 20% w / v, the first compound in a concentration of 0.005% w / v to 30% w / v, and the second compound in a concentration of 12% w / v to 50% w / v.

[0032] In some embodiments, the composition comprises 0.005% w / v to 10% w / v of the therapeutic compound, 0.1% w / v to 10% w / v of the first compound, 15% w / v to 25% w / v of the second compound, and 30% w / v to 50% w / v of water.

[0033] In some embodiments, the composition comprises 1% w / v to 8% w / v of the therapeutic compound, 0.5% w / v to 8% w / v of the first compound, 15% w / v to 25% w / v of the second compound, and 30% w / v to 50% w / v of water.

[0034] In some embodiments, the composition comprises 2% w / v to 6% w / v of the therapeutic compound, 1% w / v to 6% w / v of the first compound, 15% w / v to 25% w / v of the second compound, and 30% w / v to 50% w / v of water.

[0035] In some embodiments, the compositions of the present invention further comprise one or more additives. Additives suitable for use with the compositions of the present invention include an alcohol, a terpene, a terpenoid, bupivacaine, an alkanol, a phenols, a sulfoxide, a glycol, a fatty acid or a derivative thereof, and combinations thereof. Alcohols suitable for use with the compositions of the present invention include one or more Ci to Cs linear or branched alcohols, preferably one or more Ci to Ce linear or branched alcohols, and most preferably one or more Ci to C4 linear or branched alcohols. Terpenes and terpenoids suitable for use with the compositions of the present invention include limonene, myrcene, menthol, carvone, linalool, and combinations thereof, with limonene being preferred.

[0036] In some embodiments the compositions of the present invention further comprise limonene or bupivacaine, or a combination thereof.

[0037] The present invention is also directed to methods of administering a therapeutically effective amount of the compositions of the present invention to a subject in need thereof. In some embodiments, a subject in need of treatment suffers from otitis media.BRIEF DESCRIPTION OF THE FIGURES / DRA WINGS

[0038] FIG. 1 provides a graphic representation of the cumulative permeation of ciprofloxacin across healthy chinchilla tympanic membranes ex vivo (n = 4) for hydrogels containing 18% P407, 4% ciprofloxacin (“cip”), and the chemical permeation enhancers methyl laurate (“ML”), sodium dodecyl sulfate (“SDS”), or the combination of bupivacaine, limonene, and SDS (“3CPE(SDS)”). Data are mean ± SD, statistical analysis performed using two-way analysis of variance (ANOVA) with Dunnetf s test vs. [P407 + cip], ** indicates a statistically significant result with p < 0.005.

[0039] FIG. 2 provides a graphic representation of the release profile of ciprofloxacin from hydrogel compositions as measured using an in vitro diffusion system (n=3) containing 18% P407, 4% ciprofloxacin (“cip”), and the chemical permeation enhancers methyl laurate (“ML”), sodium dodecyl sulfate (“SDS”), or the combination of bupivacaine, limonene, and SDS (“3CPE(SDS)”). Data are mean ± SD, statistical analysis performed using two-way analysis of variance (ANOVA) with Dunnetfs test vs. [P407 + cip], * p < 0.05, ** p < 0.005, *** p < 0.0005.

[0040] FIG. 3A is an illustration of the supported lipid bilayer (SLB) formed on a PEDOT:PSS-coated electrode and its equivalent electrical circuit.

[0041] FIG. 3B is a graphic representation of illustrative impedance data showing the signature “chair- like” signal for SLB.

[0042] FIGs. 4A-4D provide graphic representations of impedance measurements taken for the bare electrode (baseline); after formation of a supported lipid bilayer using 1- palmitoyl-2-oleoyl-glycero-3-phosphocholine (“POPC”); and after 30 min of treatment with diluted hydrogel compositions containing: P407 alone (FIG. 4A); P407 and methyl laurate (“ML”) (P407+ML, FIG. 4B); P407 and ciprofloxacin (“cip”) with no permeation enhancer (P407+cip, FIG. 4C); and P407, ciprofloxacin (“cip”), and methyl laurate (“ML”) (P407+cip+ML, FIG. 4D).

[0043] FIG. 5 provides a graph of representative microelectrode EIS measurements for before SLB formation (baseline), after SLB formation (POPC SLB), and after SLB was incubated with diluted [P407], [P407 + cip], [P407 + ML], or [P407 + cip + ML] compositions.

[0044] FIG. 6 provides a graphic representation of the timeline utilized for in vivo experiments performed using a chinchilla otitis media model.

[0045] FIGs. 7A-7D are photographs of: a healthy chinchilla tympanic membrane (FIG. 7A); a chinchilla tympanic membrane infected with Nontypeable Haemophilus influenzae (“NTHi”) (FIG. 7B); a chinchilla tympanic membrane infected with NTHi following application of a hydrogel composition containing P407, ciprofloxacin (“cip”), and 2% methyl laurate onto the tympanic membrane through the outer ear canal (P407 + cip + 2% ML, FIG. 7C); and a chinchilla tympanic membrance infected with NTHi following application of a hydrogel composition containing P407, ciprofloxacin (“cip”), and a combination of bupivacaine, limonene, and SDS (“3CPE(SDS)”) (P407 + cip + 3CPE(SDS), FIG. 7D), which gelled during the injection before reaching the tympanic membrane. In FIGs. 7A-7B, the arrow points towards the tympanic membrane. The scale bar in all images FIGs. 7A-7D is 2 mm.

[0046] FIG. 8A provides a graphic representation of the percentage of ears infected with NTHi (non-zero CFU count from the middle ear fluid) before (i.e., at Day 0) and after receiving treatment with [P407 + cip] (n = 4), [P407 + cip + 3CPE(SDS)] (n = 4), and [P407 + cip + 2% ML] (n = 6), or no treatment (n = 4). Statistical analysis were performed using two-way ANOVA with Dunnett’s test vs. [untreated] for day 7, ** p < 0.005.

[0047] FIG. 8B provides a graphic representation of the CFU count of NTHi in middle ear fluids extracted from the same animals as FIG. 8A. For illustration purposes, the LoglO value for CFU measurements of zero was represented as one instead of negative infinity. All data are median and interquartile range.

[0048] FIG. 8C provides a graphic representation of the concentration of ciprofloxacin in the middle ear fluid extracted from the same animals used for the data in FIGs. 8A-8B. Data are mean ± Standard Error of Mean (SEM).

[0049] FIGs. 9A-9E provide representative images showing section tympanic membrane from healthy and NTHi-infected chinchillas after 7 days of treatment, with Gram staining.

[0050] FIGs. 10A-10E provide representative images showing section tympanic membrane from healthy and NTHi-infected chinchillas after 7 days of treatment, with Gram staining. The black arrows indicate clusters of bacteria. ME: middle ear, OE: outer ear, scale bar = 200 pm.

[0051] FIG. 11 provides a graphic representation of the observed phenomenon that with increasing temperature, a solution containing 18% P407 is disorders “unimers” at temperatures at or below 20 °C, then forms spherical micelles that are disordered in thetemperature range of 25 °C to 26.5 °C, and which then order into a physical hydrogel at temperatures at about 27 °C, as seen by rheology (plotted on logarithmic scale). Not being bound by any particularly theory, the PPO block within P407 dehydrates, as shown by the endothermic peak in the differential scanning calorimetry (DSC) curve, as temperature increases.

[0052] FIG. 12 provides a graphic representation of Small Angle X-ray Scattering (SAXS) measurements for neat P407 every from 10 °C to 50 °C measured every 5 °C (indicated by symbols), where the ID traces show broad features indicative of disordered micelles at 25 °C (black) prior to ordering onto an Face Centered Cubic (“FCC”) lattice with increasing temperature. The position of the Bragg peaks and corresponding Miller indices for the FCC-structure are highlighted with black triangles.

[0053] FIGs. 13A-13B provide a graphic representation of rheology data (plotted on a linear scale) for solutions containing P407, P407+2% SDS, P407+2% ML (FIG. 13A) and P407, P407+cip, P407+2% ML, and P407+cip+2% ML (FIG. 13B).

[0054] FIG. 14 provides a graphic representation of Differential Scanning Calorimetry (DSC) data showing that in 18% P407 solutions with 2% SDS, the temperature-dependent thermodynamic micellization transition was not observed while in 18% P407 solutions with 2% methyl laurate (“ML”), the transition was preserved.

[0055] FIGs. 15A-15B provide a graphic representation of 1-dimensional SAXS traces and 2-D patterns at 35 °C. FIG. 15C provides a graphic representation of micelle radius (Rmic) determined via SAXS as a function of ML concentration for compositions containing 18% (w / v) P407 and 4% (w / v) CIP.

[0056] FIG. 16 provides a graphical representation of the decay coefficient (F) determined via multi-angle Dynamic Light Scattering (DLS) plotted as a function of q- squared (“q2”) for compositions containing 1% P407 with 0.1% methyl laurate (“ML”) or 0.1% SDS. Linear fitting of these data bound to an intercept of zero (dashed lines) were used to extract the diffusion coefficient which is related to Rh via the Stokes-Einstein relationship. Addition of SDS dramatically decreases the Rh relative to compositions with P407 or P407 + ML.

[0057] FIGs. 17A-B are representative images of a gel containing neat 18% P407 at 37 °C (FIG. 16A), which are optically clear, and a gel containing 18% P407 and 2% methyl laurate (“ML”) (FIG. 16B), which are cloudy. A representative optical microscopy image of the gel containing 18% P407 and 2% methyl laurate (“ML”) (inset of FIG. 16B) shows thatthe presence of ML resulted in the formation of micron-sized oil droplets. Scale bar = 200 m in both insets.DETAILED DESCRIPTION

[0058] Before the present compositions and methods, among others, are described, it is to be understood that this invention is not limited to the particular processes, compositions, or methodologies described, as these may vary. It is also to be understood that the terminology used in the description is for the purpose of describing the particular versions or embodiments only and is not intended to limit the scope of the present invention which will be limited only by the appended claims. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of embodiments of the present invention, the preferred methods, devices, and materials are now described. All publications mentioned and / or referenced herein are incorporated by reference in their entirety. Nothing herein is to be construed as an admission that the invention is not entitled to antedate such disclosure by virtue of prior invention.

[0059] Throughout this disclosure, the description refers to compositions and methods of using the compositions. Where the disclosure describes or claims a feature or embodiment associated with a composition, such a feature or embodiment is equally applicable to the methods of using the compositions. Likewise, where the disclosure describes or claims a feature or embodiment associated with a method of using a composition (e.g., a method of treatment, method of administration, and / or other method of use), such a feature or embodiment is equally applicable to the compositions disclosed herein.

[0060] Reference to values stated in ranges include each and every value within that range. All ranges are inclusive and combinable. When values are expressed as approximations, by use of the antecedent “about,” it will be understood that the particular value forms another embodiment. Reference to a particular numerical value includes at least that particular value, unless the context clearly dictates otherwise.

[0061] It is to be appreciated that certain features of the disclosed compositions and methods which are, for clarity, described herein in the context of separate embodiments, may also be provided in combination in a single embodiment. Conversely, various features of the disclosed compositions and methods that are, for brevity, described in the context of a single embodiment, may also be provided separately or in any subcombination.

[0062] As used herein, the singular forms “a,” “an,” an,” and “the” include the plural.

[0063] Various terms relating to aspects of the description are used throughout the specification and claims. Such terms are to be given their ordinary meaning in the art unless otherwise indicated. Other specifically defined terms are to be construed in a manner consistent with the definitions provided herein.

[0064] As used herein, “composition” refers to a composition, pharmaceutical composition, and / or unit dosage form suitable for administration to a subject.

[0065] As used herein, “pharmaceutically acceptable” refers to a salt form, carrier, diluent, adjuvant, or excipient that is compatible with the compositions of the present invention and the other ingredients of a pharmaceutical composition such that the composition is suitable for pharmaceutical use and not deleterious to the recipient thereof.

[0066] As used herein, “administering” refers to providing a composition described herein to a subject in need thereof by ototopical or topical application, or other means that enables the compositions of the present invention to have beneficial effect(s) or to have a targeted effect(s) on a specific location of the body. “Administering” a composition may be accomplished by any method that provides a localized administration of the compositions to an area of the body requiring such treatment by known techniques.

[0067] A “therapeutically effective amount” or “effective amount” of a composition of the present invention is a predetermined amount calculated to achieve a desired effect. For example, a desired effect can be to inhibit, block, or reverse the activation, migration, proliferation, or alteration of cellular function, while preserving the normal function of normal cells. The activity contemplated by the compositions and methods described herein includes both medical therapeutic and / or prophylactic treatment, as appropriate, and the compositions and methods of the invention can be used to provide improvement in any of the conditions described. It is also contemplated that the compositions described herein may be administered to healthy subjects or individuals not exhibiting symptoms but who may be at risk of developing a particular disorder. The specific dose of a compound administered according to this invention to obtain therapeutic and / or prophylactic effects will, of course, be determined by the particular circumstances surrounding the case, including, for example, the composition administered, the route of administration, and / or the condition being treated. However, it will be understood that the chosen dosage ranges are not intended to limit the scope of the invention in any way. A therapeutically effective amount of a composition of this invention is typically an amount such that when administered it is sufficient to achieve a beneficial effect on the subject.

[0068] The terms “treat,” “treated,” and / or “treating” as used herein refer to both therapeutic treatment and prophylactic or preventative measures, wherein the object is to prevent or slow down (lessen) an undesired physiological condition, disorder, or disease, or to obtain beneficial or desired clinical results. For the purposes of this invention, beneficial or desired results include, but are not limited to, alleviation of symptoms; diminishment of the extent of the condition, disorder, or disease; stabilization (i.e., not worsening) of the state of the condition, disorder, or disease; delay in onset or slowing of the progression of the condition, disorder, or disease; amelioration of the condition, disorder, or disease state; and remission (whether partial or total), whether detectable or undetectable, or enhancement or improvement of the condition, disorder, or disease.

[0069] The term “subject,” as used herein, describes an organism, including mammals, to which treatment with the compositions and compounds according to the subject disclosure can be administered. Mammalian species that can benefit from administration of the compositions of the present invention by the disclosed methods include, but are not limited to, apes, chimpanzees, orangutans, humans, monkeys; and other animals such as dogs, cats, horses, cattle, pigs, sheep, goats, chickens, mice, rats, guinea pigs, and hamsters. Typically, the subject is a human.

[0070] In preferred embodiments, the compositions of the present invention comprise a “pseudo-surfactant assembly” between the therapeutic compound and the first compound. As used herein, a “pseudo-surfactant assembly” is a reversible complex that enhances tissue permeability of the therapeutic compound while retaining the bulk structure and rheological properties of the composition that are attributable to the second compound. As disclosed herein, the pseudo-surfactant assembly can be formed by ionic and / or Hydrogen-bonding interactions between the therapeutic compound and the first compound. In preferred embodiments, a pseudo-surfactant assembly is formed by Hydrogen-bonding interaction(s) between the therapeutic compound and first compound. As further disclosed herein, a pseudo-surfactant assembly between the therapeutic compound and first compound can be characterized using a variety of analytical techniques, including, but not limited to differential scanning calorimetry (DSC), dynamic light scattering (DLS), optical microscopy, small-angle X-ray scattering (SAXS), and / or small- amplitude oscillatory rheology.

[0071] The compositions of the present invention are generally suitable for use with any therapeutic compound having a molecular weight of about 200 g / mol to about 1,000 g / mol, and that is at least one of: ionized in aqueous solution at a pH of 3 to 8, and / or includes a Hydrogen-bond donor, and / or includes a Hydrogen-bond acceptor functional group.

[0072] In some embodiments, the therapeutic compound has a molecular weight of 225 g / mol to about 900 g / mol, about 250 g / mol to about 800 g / mol, or about 300 g / mol to about 1,000 g / mol.

[0073] In some embodiments, the therapeutic compound has low solubility in water or is substantially insoluble in water. In some embodiments, the solubility of the therapeutic compound in water is less than 0.1 g / L at 20 °C, or less than 0.01 g / L at 20 °C.

[0074] In some embodiments, the therapeutic compound is a quinolone antibiotic, a tetracycline antibiotic, a macrolide antibiotic, an aminoglycoside, a steroid, or a combination thereof any of which is ionized in aqueous solution at a pH of 3 to 8, and / or includes a Hydrogen-bond donor and / or Hydrogen-bond acceptor functional group.

[0075] In some embodiments, the therapeutic compound is a quinolone antibiotic or a pharmaceutically acceptable salt thereof. In some embodiments, the therapeutic compound is a quinolone antibiotic selected from the group consisting of: ciprofloxacin, garenoxacin, gatifloxacin, gemifloxacin, levofloxacin, moxifloxacin, a pharmaceutically acceptable salt thereof, and combinations thereof. In some embodiments the therapeutic compound is ciprofloxacin or a pharmaceutically acceptable salt thereof.

[0076] In some embodiments, the therapeutic compound is a tetracycline antibiotic or a salt thereof. In some embodiments, the therapeutic compound is a tetracycline antibiotic selected from: tetracycline, chlortetracycline, oxytetracycline, demeclocycline lymecycline, methacycline, minocycline, rolitetracycline, doxycycline, tigecycline, eravacycline, sarecycline, omadacycline, salts thereof, and combinations thereof.

[0077] In some embodiments, the therapeutic compound is a macrolide antibiotic or a salt thereof. In some embodiments, the therapeutic compound is a macrolide antibiotic selected from: erythromycin, azithromycin, clarithromycin, dirithromycin, roxithromycin, telithromycin, cethromycin, solithromycin, Carbomycin A, josamycin, kitasamycin, midecamycin, oleandomycin, spiramycin, troleandomycin, tylosin, boromycin, tacrolimus, sirolimus, pimecrolimus, amphotericin B, nystatin, natamycin, rimocidin, filipin, candicin, hamycin, perimycin, dermostatin, salts thereof, and combinations thereof.

[0078] In some embodiments, the therapeutic compound is an aminoglycoside or a salt thereof. In some embodiments, the therapeutic compound is an aminoglycoside selected from: gentamicin, amikacin, tobramycin, neomycin B, neomycin C, neomycin E, streptomycin, plazomycin, kanamycin, vancomycin, amikacin, tobramycin, dibekacin, gentamicin, sisomicin, netilmicin, salts thereof, and combinations thereof.

[0079] In some embodiments, the therapeutic compound is a steroid or a salt thereof. In some embodiments, the therapeutic compound is a steroid selected from: dexamethasone, hydrocortisone, cortisone, prednisone, prednisolone, methylprednisolone, betamethasone, triamcinolone, deflazacort, fludrocortisone, deoxycorticosterone, aldosterone, beclomethasone, triamcinolone, paramethasone, fluprednisolone, salts thereof, and combinations thereof.

[0080] Pharmaceutically acceptable salts of the therapeutic compounds for use with the present invention include acid-addition salts. Suitable pharmaceutically-acceptable acid addition salts of compounds within the scope of the present invention may be prepared from anions derived from inorganic or organic acids, or a combination thereof. Examples of salts derived from inorganic acids include but are not limited to chloride, bromide, iodide, nitrite, nitrate, carbonate, sulfate, phosphate, tetrafluoroborate, and combinations thereof. Suitable organic acids include aliphatic, cycloaliphatic, aromatic, araliphatic, heterocyclic, carboxylic, sulfonic, and combinations thereof. Representative organic acids include but are not limited to formate, acetate, propionate, succinate, glycolate, gluconate, lactate, malate, tartrate, citrate, ascorbate, glucuronate, maleate, fumarate, pyruvate, aspartate, glutamate, benzoate, anthranilate, mesylate, salicylate, 4-hydrobenzoate, phylacetate, mandelate, embonate, methanesulfonate, ethanesulfonate, benzenesulfonate, pantothenate, 2- hydroxyethanesulfonate, toluenesulfonate, sulfanilate, cyclohyexylaminosuflonate, stearate, algenate, hydrobutyrate, galactarate and galactumoate, and combinations thereof. In some preferred embodiments, a hydrochloride salt of a therapeutic compound is preferred.

[0081] In some embodiments, the therapeutic compound is present in a concentration of about 0.005% w / v to about 10% w / v, about 0.5% w / v to about 10% w / v, preferably about 1% w / v to about 6% w / v, or most preferably about 4% w / v.

[0082] In some embodiments, the compositions of the present invention further comprise one or more additional therapeutic compounds. Additional therapeutic compounds suitable for use with the present invention include analgesics such as bupivacaine, lidocaine, tetracaine, benzocaine, and prilocaine.

[0083] In some embodiments, an additional therapeutic compound is present in a concentration of about 0.005% w / v to about 10% w / v, about 0.5% w / v to about 10% w / v, about 1% w / v to about 8% w / v, or about 2% w / v to about 6% w / v.

[0084] The inventive compositions comprise a “first compound” which is generally a neutral or non-ionized compound having permeation enhancing functionality, which refers to an ability to increase the flux of a therapeutic compound through a biologic barrier.

[0085] In some embodiments, the first compound is selected from an ester, a diester, or an oligo-ester having 3-10 ester groups (e.g. 3, 4, 5 ester groups). In some embodiments, the first compound is selected from an ester, a diester, or an oligo-ester comprising a Ce to Cis carbon chain, while esters, diesters, and oligo-esters comprising a Ce to Ci6 carbon chain, a Ce to Cu carbon chain, or a Ce to C12 carbon chain can also be used. Similarly, esters, diesters, and oligo-esters comprising a Cs to Cis carbon chain, a C10 to Cis carbon chain, or a C12 to Cis carbon chain can also be used.

[0086] In some embodiments, the first compound comprises a Ce to Cis fatty acid ester, a Ce to Ci6 fatty acid ester, a Ce to C14 fatty acid ester, a Ce to Cis fatty acid ester, a Cs to Cis fatty acid ester, a C10 to Cis fatty acid ester, or a combination thereof. Fatty acid esters for use with the inventive compositions can include an n-alkyl or branched alkyl chain and a methyl, ethyl, propyl, isopropyl, or butyl ester group, or a mixture thereof.

[0087] In some embodiments, the first compound comprises a Ce to Cis fatty acid methyl ester, a Ce to Cie fatty acid methyl ester, a Ce to C14 fatty acid methyl ester, a Cs to Cis fatty acid methyl ester, a C10 to Cis fatty acid methyl ester, a C12 to Cis fatty acid methyl ester, or a combination thereof. In some embodiment, the fatty acid methyl ester comprises methyl laurate.

[0088] In some embodiments, the first compound consists essentially of a Ce to Cis fatty acid methyl ester, a Ce to Cie fatty acid methyl ester, a Ce to C14 fatty acid methyl ester, a Cs to C is fatty acid methyl ester, a C10 to Cis fatty acid methyl ester, a C12 to Cis fatty acid methyl ester, or a combination thereof. In some embodiments, the permeation enhancer consists essentially of methyl laurate.

[0089] In some embodiments, the first compound consists of a Ce to Cis fatty acid methyl ester, a Ce to Cie fatty acid methyl ester, a Ce to C14 fatty acid methyl ester, a Ce to C12 fatty acid methyl ester, a Cs to Cis fatty acid methyl ester, a C10 to Cis fatty acid methyl ester, a C12 to Cis fatty acid methyl ester, or a combination thereof.

[0090] In some embodiments, the first compound comprises a fatty acid short chain ester. As used herein, “short chain” refers to a Ci to C4 alkyl chain, which is optionally branched. Generally, a fatty acid shorty chain ester has the structure R1-O-C(=O)-R2, where R1is a “short chain” alkyl group as defined herein and R2is a C10 to C20 n-alkyl or branched alkyl chain. In some embodiments, the fatty acid short chain ester is selected from: methyl caprate, ethyl caprate, propyl caprate, iso-propyl caprate, butyl caprate, methyl laurate, ethyl laurate, propyl laurate, iso-propyl laurate, butyl laurate, methyl myristate, ethyl myristate, propyl myristate, iso-propyl myristate, butyl myristate, methyl palmitate, ethyl palmitate, propylpalmitate, iso-propyl palmitate, butyl palmitate, methyl stearate, ethyl stearate, propyl stearate, iso-propyl stearate, butyl stearate, and combinations thereof. In some embodiments, the fatty acid short chain ester is methyl laurate.

[0091] The first compound is generally present in any concentration suitable to facilitate the permeation of the therapeutic compound through a biologic barrier, such as the skin, a membrane, eardrum, or other barrier. In some embodiments the first compound is present in a concentration of about 0.1% w / v to about 20% w / v, about 0.2% w / v to about 18% w / v, about 0.5% w / v to about 15% w / v, or preferably about 1% w / v to about 10% w / v, about 1% w / v to about 5% w / v, or about 1% w / v to about 4% w / v.

[0092] In some embodiments, the first compound comprises a fatty acid methyl ester and is present in the composition in a concentration of about 0.5% w / v to about 10% w / v, about 0.5% w / v to about 5% w / v, or about 0.5% w / v to about 4% w / v. In some embodiments, the first compound is a fatty acid methyl ester present in the composition in a concentration of about 1% w / v to about 4% w / v. In some embodiments, the first compound is a fatty acid methyl ester present in the composition in a concentration of about 2% w / v.

[0093] In some embodiments, the first compound comprises a fatty acid methyl ester present in a concentration of about 0.5% w / v to about 5% w / v, more preferably about 1% w / v to about 4% w / v, and most preferably about 2% w / v.

[0094] The amounts of the therapeutic compound and first compound can also be selected on the basis of a molar ratio suitable for the formation of a pseudo-surfactant assembly. In some embodiments, the therapeutic compound and first compound are present in the compositions of the present invention at a molar ratio of about 1:4 to about 4:1 and any values therewith and any subranges therebetween, and preferably about 1:3 to about 3:1 or about 1:2 to about 2:1, or most preferably about 1:1.

[0095] In some embodiments, the therapeutic compound comprising a Hydrogen-bound donor functional group, a Hydrogen-bond acceptor functional group, or a combination thereof; and the first compound comprises a Hydrogen-bond acceptor functional group, a Hydrogen-bond acceptor functional group, or a combination thereof, and the therapeutic compound and first compound interact via one or more Hydrogen-bonds to form a pseudosurfactant assembly.

[0096] In some embodiments, the therapeutic compound interacts with the one or more functional groups of the first compound via one or more hydrogen bonds to form an assembly. In some embodiments, the therapeutic compound comprises one or more Hydrogen bound donors having N, O, F, or any combination, and the first compound comprises one ormore Hydrogen bound acceptors (e.g. an ester group) to interact with the hydrogen bound donors of the therapeutic compound to form a pseudo-surfactant assembly. In other embodiments, the therapeutic compound comprises one or more Hydrogen bound acceptor and the first compound comprises one or more Hydrogen bound donor to interact with the therapeutic compound to form a pseudo-surfactant assembly.

[0097] As discussed herein, the presence of an ionic surfactant in the compositions of the present invention in a concentration sufficient to disrupt the formation of a pseudo-surfactant assembly between the therapeutic compound and the first compound should be avoided. In some embodiments, the compositions of the present invention contain 2% w / v or less of an ionic surfactant, 1% w / v or less of an ionic surfactant, 0.5% w / v or less of an ionic surfactant, 0.2% w / v or less of an ionic surfactant, or 0.1% or less of an ionic surfactant. In some embodiments, the compositions of the present invention are substantially free of an ionic surfactant, for example, 100 ppm or less of an ionic surfactant, 50 ppm or less of an ionic surfactant, or 20 ppm or less of an ionic surfactant. In some embodiments, the compositions of the present invention do not contain an ionic surfactant, for example, in any detectable amount.

[0098] In particular, the ionic surfactant sodium dodecyl sulfate (“SDS”) remains a very popular and effective chemical permeation enhancer for the administration of therapeutic compounds across biologic barriers. However, SDS has been reported to cause more skin irritation than most fatty acid esters (see Ref. 1), given its ability to not only perturb the lipid lamellae in the stratum corneum (see Ref. 73), but to also solubilize the proteins in the stratum corneum, causing corneocyte swelling and detachment (see Refs. 74-75). What is more, SDS can greatly interfere with the micellization and gelation of P407 hydrogel, which is a critical component of this in situ gelling composition. Thus, in some embodiments the compositions of the present invention contain 0.5% w / v or less of SDS, 0.2% w / v or less of SDS, or 0.1% or less of SDS. In some embodiments, the compositions of the present invention are substantially free of SDS, for example, 100 ppm or less of SDS, 50 ppm or less of SDS, or 20 ppm or less of SDS. In some embodiments, the compositions of the present invention do not contain SDS, for example, in any detectable amount.

[0099] The inventive compositions comprise a “second compound” which is generally a hydrophilic, non-ionic or neutral surfactant. In preferred embodiments, the second compound forms a hydrogel.

[0100] In some embodiments, the second compound comprises a hydrophilic non-ionic surfactant having the structure of formula I:wherein a is independently an integer of about 50 to about 150, preferably about 75 to about 125, and most preferably about 100; and b is independently an integer of about 40 to about 70, and preferably about 50 to about 60, and most preferably about 55. In some embodiments, a is an integer of about 50 to about 150 and b is an integer of about 40 to 70, preferably a is an integer of about 75 to about 125 and b is an integer of about 50 to about 60, and more preferably a is an integer of 100 and b is an integer of 55. In some embodiments, a is 156 and b is 101.

[0101] In some embodiments, the second compound is a non-ionic surfactant or a neutral surfactant selected from a poloxamer or a derivative thereof, a reverse poloxamer or a derivative thereof, a polyethylene glycol polymer, and a combination thereof.Pharmaceutically acceptable poloxamers and derivatives thereof, reverse poloxamers and derivatives thereof, and polyethylene glycol polymers are described in the Handbook of Pharmaceutical Excipients, Sixth Edition, the relevant sections of which are incorporated by reference in the entirety.

[0102] In some embodiments, the second compound is a non-ionic surfactant selected from a polysorbate, sodium lauryl sulfate, poloxamer, polyoxyl 40 hydrogenated castor oil, lauroyl polyoxyl-32 glycerides, mannide monooleate, propylene glycol monocaprylate, and a combination thereof.

[0103] In some embodiments, the second compound is a non-ionic surfactant is selected from one or more polysorbates (e.g. polysorbate 20, polysorbate 80), one or more poloxamers (e.g. P407, P188, and / or P338), reverse poloxamers and any derivatives, polyoxyethylene (160), polyoxypropylene (30) glycol, MAKON 17R2, MAKON 17R4, pluronic diacrylate, poloxamer dimethacrylate, a PEG-based polymer (e.g. PEGDA, PEGMA, PLGA-PEG- PLGA, PEG-PCL-PEG), and / or any combinations thereof.

[0104] In some embodiments, the second compound is selected from P407, P188, P338, MAKON 17R2, MAKON 17R4, poloxamer / pluronic diacrylate, poloxamer dimethacrylate, PEGDA, PEGMA, PLGA-PEG-PLGA, PEG-PCL-PEG, and a combination thereof.

[0105] The second compound can be present in the compositions in any concentration that forms a stable hydrogel. In some embodiments, the second compound comprises a hydrophilic non-ionic surfactant and is present in the compositions in a concentration of about 10% w / v to about 25% w / v, or about 12% w / v to about 25% w / v, or preferably about15% w / v to about 25% w / v. In some embodiments, the second compound comprises a hydrophilic non-ionic surfactant and is present in the compositions in a concentration of about 12% w / v to about 30% w / v. In some embodiments, the second compound comprises a hydrophilic non-ionic surfactant and is present in the compositions in a concentration of about 15% w / v to about 25% w / v, or about 15% w / v to about 25% w / v. In some embodiments, the second compound comprises a hydrophilic non-ionic surfactant and is present in the compositions in a concentration of about 18% w / v.

[0106] Notably, the most preferred first compound (methyl laurate) and second compound (P407) have been used in FDA-approved otic and intra-tympanic products as well as topical pharmaceuticals such as transdermal patches containing fentanyl or testosterone (see Refs. 28, 29, 69, 77, 78). Thus, the compositions of the present invention do not require further regulatory review and approval in order to be administered to mammals, and in particular humans.

[0107] In some embodiments, the second compound is a thermoresponsive polymer, a thermoresponsive block copolymer, or a combination thereof. As used herein, a “thermoresponsive” or “temperature-responsive” polymer refers to polymers that undergo discontinuous changes in their physical properties as a function of temperature. Relevant properties for the inventive compositions disclosed herein include, but are not limited to, solubility, three-dimensional packing, hydrogen bonding, hydrogel formation, micelle formation, phase separation, and the like.

[0108] In some embodiments, the compositions of the present invention include P407 as the second compound, which is a thermoresponsive polymer that undergoes gelation in aqueous solutions with increasing temperature, which is driven by changes in polymer solubility. P407 is an ABA triblock polymer composed of poly(ethylene oxide) (PEO) endblocks and a polypropylene oxide) (PPO) midblock. With increasing temperature, the interactions between water and the PPO midblock become less favorable, driving the formation of spherical micelles composed of PPO cores and PEO coronas (see Refs. 32, 44- 49). When a critical volume fraction of micelles is achieved, the micelles order into cubic packings, causing the low-viscosity solutions to gel (see Refs. 32, 50, 51).

[0109] In some embodiments, the inventive composition is thermosensitive with a transition from a liquid at a first temperature to a hydrogel at a second temperature. In some embodiments, the compositions of the present invention form a stable hydrogel at a temperature of about 20 °C to about 40 °C, about 25 °C to about 45 °C, or about 25 °C to about 40 °C. In some embodiments, the compositions of the present invention have a sol-geltransition temperature at about 4 °C to about 35 °C, about 6 °C to about 32 °C, or about 8 °C to about 30 °C.

[0110] In some embodiments, the pseudo-surfactant assembly formed by the therapeutic compound and first compound further interacts with the second compound to form a micelle assembly, a hydrogel, or a combination thereof. In some embodiments, the pseudo-surfactant assembly interacts with the second compound to form a micelle assembly in a solution or a hydrogel with water.

[0111] In some embodiments, the composition and / or the second compound is thermosensitive with a transition from a liquid at a first temperature (e.g less than 15 °C such as 4 °C) to a hydrogel at a second temperature (e.g. greater than 20 °C such as 30 °C to 37 °C). In some embodiments, the composition is a stable hydrogel in a temperature of about 20 °C to about 40 °C, including any values therewithin and / or any subranges therebetween, preferably about 30 to about 37 °C. In some embodiments, the composition and / or the second compound has a sol-gel transition temperature in a range of about 1 °C to about 35 °C, including any values therewithin and / or any subranges therebetween, preferably about 5 °C to about 2 °C.

[0112] In some embodiments, the composition further comprises one or more additives, one or more additional therapeutic compounds, or any combinations thereof. In some embodiments, the one or more additives are selected from one or more terpenes (e.g. limonene), alcohols, alkanols, phenols, sulfoxides, glycols, fatty acids and fatty acid derivatives. In some embodiments, one or more additional therapeutic compounds is bupivacaine, or other small molecule analgesics.

[0113] The present disclosure is also directed to methods of treating disorders that require or benefit from the transdermal, transmembrane, and / or transtympanic administration of an antibiotic. In some embodiments, the present invention is directed to methods of treating otitis media, the methods comprising transtympanically administering a therapeutically effective amount of a composition to a subject in need thereof.

[0114] In some embodiments, the composition of the present invention comprises 0.1% w / v to 20% w / v of the therapeutic compound including any values therewith and any subranges therebetween, 0.1% w / v to 20% w / v of the first compound including any values therewith and any subranges therebetween, 10% w / v to 30% w / v of the second compound including any values therewith and any subranges therebetween, and optionally 30% w / v to 50% % w / v of water including any values therewith and any subranges therebetween.

[0115] In some embodiments, the present invention is directed to a composition comprising: a hydrophilic non-ionic surfactant having the structure of Formula I:wherein a is an integer from about 75 to about 125, and b is an integer from about 50 to about 60, and wherein the hydrophilic non-ionic surfactant is present in a concentration of about 15% w / v to about 25% w / v; methyl laurate, in a concentration of about 1% w / v to about 4% w / v; a quinolone antibiotic selected from the group consisting of: ciprofloxacin, garenoxacin, gatifloxacin, gemifloxacin, levofloxacin, moxifloxacin, and combinations thereof, present in a concentration of about 0.5% w / v to about 6% w / v; and water.

[0116] A few features that distinguish the disclosure over the related technologies include, but are not limited to:• Similar or enhanced permeation of the therapeutic compound compared to other compositions containing permeation enhancers.• Enhanced bioavailability of the therapeutic compound compared to other compositions containing permeation enhancers.• The ability to treat otitis media patients who do not have perforated eardrum or tympanostomy tube in place can be the subject of treatment with the present compositions and methods of treatment.

[0117] More embodiments include:• In some embodiments, the compositions further comprise a permeation enhancer. In some embodiments, the additional permeation enhancer is selected from: limonene, bupivacaine, and combinations thereof.• In some embodiments, the compositions further comprise a Ci to Cs alcohol. In some embodiments, the compositions further comprise a C2 or C3 alcohol, or a combination thereof.

[0118] In some embodiments, the present invention is directed to method of administering the compositions described herein to a subject in need of treatment with a therapeutic compound. The compositions of the present invention are particularly suitable for administering a therapeutic compound to a subject suffering from a condition that would benefit from localized (i.e., non-systemic) administration of a therapeutically effective amount of the therapeutic compound.

[0119] The methods of the present invention include administering a composition as described herein once, twice, three times, or four times per day or on an as-needed basis to treat the subject’s condition.

[0120] These detailed descriptions serve to exemplify the above general descriptions and embodiments which form part of the invention. These detailed descriptions are presented for illustrative purposes only and are not intended as a restriction on the scope of the invention.EXAMPLESExample 1: Ex vivo Drug Permeation with Ciprofloxacin-Containing Compositions

[0121] To achieve non-invasive delivery of antibiotics across the tympanic membrane, the transtympanic permeation of ciprofloxacin was quantified in the ototopical treatment of otitis media patients (i.e., patients with perforated transtympanic membranes). Referring to FIG. 1, the transtympanic drug flux was measured for three compositions, each containing 18% w / v P407 and 4% w / v ciprofloxacin: (i) [P407 + cip], which served as the baseline for the transtympanic flux of ciprofloxacin without CPEs, (ii) [P407 + cip + 2% ML], which additionally contained 2% w / v ML, and (iii) [P407 + cip + 3CPE(SDS)], which additionally contained the three chemical permeation enhancers SDS (1% w / v), limonene (2% w / v), and bupivacaine (0.5% w / v). The latter (i.e., 3CPE(SDS)) has been previously identified as the gold standard and thus served as a benchmark in this experiment (see Ref. 30).

[0122] A previously established ex vivo chinchilla model was used to measure the transtympanic drug flux. Tympanic membranes from healthy chinchillas were harvested following euthanization under CO2 inhalation in accordance with IACUC guidelines, and the auditory bullae were removed from the skull. Each bulla was excised to expose the middle ear chamber and the tympanic membrane. Immediately following dissection, the tympanic membranes were visually examined, and their electrical impedance was measured using a previously described protocol to test tissue integrity see Ref. 18).

[0123] Excised bullae were placed vertically in sterile 12-well plates, with the external ear canal facing upwards and the exposed middle ear chamber facing downwards and submerged in 3 mL of sterile lx phosphate buffered saline (PBS). Formulations (200 pL) were injected with micropipettes into the external ear canal. Bullae were kept in a humid chamber and placed in a 37 °C incubator. At pre-determined time points (1, 2, 3, 6, 12, 24, 48 hours), the saline solutions from the well plate were sampled and fresh sterile saline was added to ensure the infinite sink conditions. The samples were collected until 48 hours to avoid complications from tissue degradation thereafter. The drug concentration was determined using high-performance liquid chromatography (HPLC). Sample aliquots werediluted with HPLC grade methanol and sonicated for 10 min for protein precipitation, and then filtered with a 0.45-pm pore size membrane before HPLC.

[0124] Referring to FIG. 1, the ex vivo transtympanic permeation of ciprofloxacin within the first 12 hours was minimal for all groups (<0.2%). After 12 hours, the ciprofloxacin permeation for [P407 +cip + 3CPE(SDS)] reached 0.4 ± 0.2% and that for [P407 + cip + 2% ML] reached 0.18 ± 0.12%, both higher than 0.075 ± 0.009% achieved by the baseline composition [P407 + cip]. This trend continued at 24 hours, where [P407 +cip + 3CPE(SDS)] allowed 2.0 ± 0.7% of the ciprofloxacin to permeate across intact tympanic membranes, whereas [P407 + cip + 2% ML] enabled a ciprofloxacin permeation of 2.5 ± 1.0%, over four fold that achieved by [P407 + cip], i.e., 0.6 ± 0.2%. After 48 hours, 2.4 ± 0.6% of ciprofloxacin in [P407 + cip] permeated through the tympanic membranes, while the addition of 3CPE(SDS) and 2% w / v ML more than doubled that amount, achieving 6.3 ± 1.0% (p < 0.005 vs. P407 + cip) and 6.6 ± 1.2% (p < 0.005 vs. P407 + cip), respectively.

[0125] The permeation enhancement achieved by [P407 + cip + 2% ML] vs. [P407 +cip + 3CPE (SDS)] illustrates the outstanding permeation enhancement of methyl laurate.Although methyl laurate has previously been considered a less effective chemical permeation enhancer compared to SDS, the permeation enhancement achieved in this study was 3.6-fold greater that previously reported for 2% w / v SDS alone (dotted line, FIG. 1).Example 2: In Vitro Release Study

[0126] Drug diffusion through a hydrogel matrix was examined using in vitro release studies, performed using a Trans well™-based set-up under infinite sink conditions. Semipermeable membrane inserts (12-mm Transwell™ insert with a polyester membrane with 0.4-pm pore size, Coming® 3460) were placed in 12-well culture plates, which acted as receiving chambers. Each hydrogel formulation was added to the insert at a volume of 200 pL / insert and allowed to gel for 20 min in an incubator kept at 37°C. The control group, 4% ciprofloxacin in water, was added at the same volume to probe the inherent diffusivity of the Transwell™ insert. Next, 1.5 mL of pre-warmed 0.9% NaCl saline was added to the receiving chamber. At each time point (1, 2, 3, 6, 12, 24, 48, 72, 120 hours), the saline in the receiving chamber was retrieved for analysis and each insert was placed into a new well with the same amount of fresh saline (i.e., 1.5 mL). Samples were diluted in MilliQ water as needed, filtered with a 0.45-pm (pore size) PTFE membrane, then analyzed by high- performance liquid chromatography (HPLC) to determine the concentration of ciprofloxacin hydrochloride. For these measurements, HPLC-grade acetonitrile, methanol, and water wereobtained from Fisher Chemical and HPLC-grade trifluoroacetic acid (TFA) was obtained from Sigma- Aldrich. The HPLC was performed on a Shimadzu LC-2030C 3D with a Cl 8 column, 4.6 x 100 mm, 2.7 pm (Agilent). The mobile phase contained acetonitrile with 0.1% TFA (solvent A) and water with 0.1% TFA (solvent B). Samples (10 pl) were eluted with a gradient from A:B = 90:10 v / v to 10:90, then back to 90:10, under a flow rate of 1 mL / min. Eluents were measured for UV-Vis absorbance at 270 nm.

[0127] Referring to FIG. 2, samples were retrieved at discrete time points over the course of 120 hours to fully capture the drug release kinetics, which plateaued after 48 hours.

[0128] The cumulative drug release at 120 hours was lowered by the presence of 18% w / v P407, as shown by the cumulative release of 73.5 ± 3.5% achieved by [P407 + cip] compared to 95.6 ± 6.7% achieved by [cip in H2O]. Adding 2% w / v ML, i.e. [P407 + cip + 2% ML], had a negligible effect on drug elution, leading to a cumulative ciprofloxacin release at 120 hours of 69.5 ± 3.4%, similar to that of [P407 + cip].

[0129] Consistent with previous reports (see Ref. 33), 3CPE(SDS) reduced the cumulative drug elution at 120 h to 51.0 ± 3.5% (p < 0.005 vs. [P407 + cip]). This reduction in drug elution is likely due to insoluble aggregates that form via electrostatic interactions and slow drug diffusion, as SDS has a negatively charged sulfate group and ciprofloxacin has a protonated amine group (see Refs. 12-14, 32).

[0130] To confirm that the slow drug elution from the composition [P407 + cip + 3CPE(SDS)] was due to the ionic surfactant SDS, in vitro drug release from [P407 + cip + 1% w / v SDS] was also examined. Referring to EIG. 2, the addition of 1% SDS significantly lowered the drug release at 120 h to 36.6 ± 2.5% (p < 0.0005 vs. [P407 + cip]). Upon increasing the concentration of SDS to 2% w / v, the drug elution at 120 h was further reduced to 20.4 ± 3.7% (p < 0.0005 vs. [P407 + cip]).

[0131] The in vitro data in PIG. 2 demonstrated that the addition of methyl laurate preserves the release kinetics of ciprofloxacin from the hydrogel.Example 3: Electrical Impedance on Supported Lipid Bilayers

[0132] In order to determine whether the observed ciprofloxacin permeation enhancement was a result of methyl laurate alone or the combined effect of methyl laurate and ciprofloxacin, experiments were conducted to compare the effect of ML-only vs. ML- ciprofloxacin on the structural integrity and permeability of supported lipid bilayers using electrochemical impedance spectroscopy.

[0133] Referring to FIG. 3A, electrochemical impedance spectroscopy measures the impedance across supported lipid bilayers that are sandwiched between two electrodes (see Refs. 18, 37). Lipid bilayers constitute the most likely path of diffusion through the stratum comeum, i.e., the uppermost layer in skin and tympanic membrane that is largely impermeable to most drugs (see Refs. 23-26). Supported lipid bilayers have been widely used as cell membrane surrogates to study the biophysical properties of membranes and their interactions with signaling molecules (see Refs. 35, 36). The effect of CPEs on the structural integrity of SLB thus provides a good prediction of their effect on tympanic membrane permeability.

[0134] The supported lipid bilayers were formed using l-palmitoyl-2-oleoyl-glycero-3- phosphocholine (POPC, FIG. 3A), a widely used phosphatidylcholine model lipid to recapitulate the phospholipids present in the cell membrane (see Refs. 38-40).

[0135] Referring to FIG. 3B, upon the formation of the supported lipid bilayers, the signal across the frequency range of 1 to 106 Hz shifted from the hockey stick-like baseline to a chair- like profile, confirming the signature supported lipid bilayers behavior that is commonly described with a capacitor and resistor in parallel, which is the equivalent circuit used to fit the EIS data. As such, a decrease in the impedance value indicates enhanced permeation across the supported lipid bilayers, and vice versa.

[0136] The supported lipid bilayers were subsequently treated by the hydrogel compositions used in the ex vivo experiment, i.e., [P407 + cip] and [P407 + cip + ML]. The compositions were diluted 20-fold in Tris-KCl buffer to minimize the mechanical perturbations to the supported lipid bilayers.

[0137] Referring to FIGs. 4A-4D and FIG. 5, after a 30-min treatment using a composition comprising [P407, FIG. 4A], [P407 + ML, FIG. 4B], or [P407 + cip, FIG. 4C], POPC- supported lipid bilayers demonstrated a largely unchanged impedance profile. The composition that did not contain ciprofloxacin, i.e., [P407 + ML], considerably increased the impedance (by 95 ± 25%) (FIG. 4B, FIG. 5), indicating reduced permeability of the lipid bilayers after the treatment. This result is likely attributed to the physisorption of ML onto the supported lipid bilayers due to ML’s strong lipophilicity, which slightly increased the supported lipid bilayers thickness without destabilizing it.

[0138] Referring to FIGs. 4A-4D and FIG. 5, while [P407] (FIG. 4A), [P407 + cip] (FIG. 4C), and [P407 + ML] (FIG. 4B) did not decrease the supported lipid bilayer impedance, the treatment with both ciprofloxacin and ML (i.e., diluted [P407 + cip + ML], FIG. 4D) caused a notable decrease by 90 ± 3% in the supported lipid bilayer impedance. This result indicatesthat ciprofloxacin and ML interacted with one another to disrupt the structural integrity of the lipid bilayer, translating to higher supported lipid bilayer permeability and corroborating the ex vivo results obtained using harvested chinchilla tympanic membranes.

[0139] Referring to FIG. 5, in order to benchmark the decrease in impedance observed with [P407 + cip + ML], supported lipid bilayers were treated with additional diluted compositions containing SDS: [P407 + SDS], [P407 + cip + SDS], [P407 + 3CPE(SDS)], and [P407 + cip + 3CPE(SDS)]. The SDS-containing compositions led to a hockey stick- like impedance profile, indicating baseline-level impedance and thus destruction of the supported lipid bilayers.

[0140] Comparing FIG. 4D and FIG. 5, the impedance of the SLB treated with [P407 + cip + ML] maintained its chair-like profile, indicating disruption, and not destruction, of the supported lipid bilayers. Not being bound by any particular theory, these results indicate improved biocompatibility of the methyl laurate-containing compositions compared to compositions containing SDS. Additionally, the comparison between the impedance of [P407 + cip + ML] and that of [P407 + cip] or [P407 + ML] illustrates the presence of interactions between methyl laurate and ciprofloxacin, indicating the formation of a pseudo-surfactant assembled from methyl laurate and ciprofloxacin.Example 4: Hydrogel Compositions For Treating Otitis Media

[0141] To confirm the effectiveness of ML as a transtympanic CPE in the P407 hydrogel with ciprofloxacin, the [P407 + cip], [P407 + cip + 3CPE(SDS)], and [P407 + cip + 2% ML] compositions were tested in vivo for treating acute otitis media in chinchillas. Chinchillas are widely accepted as OM models (see Refs. 41, 42) and have been used in preclinical testing for FDA- approved otic products (see Ref. 43).

[0142] Healthy adult chinchillas weighing 400 - 600 g were obtained from the Mutation Chinchilla Breeder Association (NY). All animal care and experiment activities were carried out in accordance with protocols approved by the Institutional Animal Care and Use Committee (IACUC), in conjunction with the Center of Animal Resources and Education (CARE) Animal Use Guidelines at Cornell University.

[0143] Otitis media infections were established by inoculating Nontypeable Haemophilus influenzae (“NTHi”) into the bulla of chinchillas. Non-typeable haemophilus influenzae (NTHi) was grown to the mid-log phase and diluted in sterile Hanks’ balanced salt solution (HBSS). The solution (100 pL, 25-75 CFU) was inoculated directly into the middle ear of chinchillas through the bulla, using aseptic techniques. Once pathogen inoculation wascompleted, chinchillas were monitored, and their TMs examined via otoscopy. After middle ear infection was established (usually at 3 days post inoculation), 200 pL of the formulations were administered through the external ear canal using a soft-tipped 22-gauge angiocatheter (without needle, Monoject™), and the animals underwent surgery for middle ear sample collection. The animals were anesthetized under isoflurane inhalation, placed in ventral recumbency, and had their tympanic bullae surgically prepped. A small surgical opening was created at the most palpable region of the tympanic bulla with a scalpel blade. Direct samples of the middle ear culture were obtained with sterile cotton swabs, and immediately streaked onto chocolate agar plates. The middle ear fluid (MEF) was retrieved through the surgical opening with a 22-gauge angiocatheter (without needle) connected to a 1 mL tuberculin syringe, without hampering TM integrity. The MEF was sampled before the treatment on day 0, and after the administration of the formulations on day 1, day 3, and day 7. The MEF (10- 20 pL) was diluted in HBSS with 10-fold serial dilution and plated onto chocolate agar plates. The number of colonies was counted to calculate the CFU of NTHi, with the lower limit of detection being 100 CFU / mL.

[0144] Referring to FIG. 6, the middle ear fluid (“MEF”) was sampled before inoculation on day 0, and after the administration of the compositions on day 1, day 3, and day 7.

[0145] Infection was defined as non-zero NTHi colony forming units (“CFU”) count from the middle ear fluid or a direct cotton swab from the bulla.

[0146] Hydrogel formulations were administered to the external ear canal of healthy or infected chinchillas. FIGs. 7 A and 7B provide images of hydrogel administered to healthy and infected chinchilla tympanic membranes. Seven days after the administration, animals were euthanized under CO2 inhalation in accordance with IACUC guidelines. The bullae were retrieved and excised to expose the TM, while the bone and tissue around the tympanic ring were carefully removed. The excised samples were immediately fixed in 10% neutral buffered formalin overnight. Decalcification, paraffin embedding, sectioning (5 pm thick), and hematoxylin and eosin staining were performed by the Section of Anatomic Pathology at the Animal Health Diagnostic Center at Cornell University (Ithaca, New York, USA; fee for service), using standard techniques. Stained specimens were examined under light microscopy (VHX optical microscope, Keyence). The thickness of the TM was measured with Fiji97. Six measurements were taken for each specimen.

[0147] Compositions were administered via the outer ear canal and placed as close to the tympanic membrane as possible. Referring to FIG. 7C and FIG. 8A, the [P407 + cip + 2% ML] composition eradicated otitis media in 83% of the treated animals within the first 24 1hours, which was maintained through day 7 (p < 0.005 vs. untreated). In contrast, the P407 + cip composition had no measurable effect on otitis media.

[0148] Referring to FIG. 7D and FIG. 8A, [P407 + cip + 3CPE(SDS)] proved difficult to administer due to its low gelation temperature, which caused the composition to transition from a liquid to a hydrogel as it was being extruded, before reaching the tympanic membrane.

[0149] Referring to FIG. 8B, the CFU count of NTHi culture recovered from the MEF showed a sharp decrease on day 1 after the treatment from a median of 1.75 x 107 to 0, which was also maintained throughout the 7-day treatment. NTHi was not eradicated in one of the six animals treated with [P407 + cip + 2% ML], but the MEF CFU count for this animal did show a 3-log reduction from day 0 to day 7, corresponding to a 99.9% reduction of the bacterial count in the middle ear, which has been considered an indication of cure. By contrast, treatment with [P407 + cip + 3CPE(SDS)] led to a 50% cure rate by day 7, with a median CFU count 7.25 x 105. The animals that were untreated or treated with [P407 + cip] remained 100% infected through day 7, with a median CFU count of 1.02 x 107 and 1.06 x 105, respectively.

[0150] Referring to FIG. 8C, the concentration of ciprofloxacin in the MEF over the course of treatment indicated a clear enhancement of drug permeation across the TM with the addition of 2% ML. The drug concentration in animals treated with [P407 + cip + 2% ML] peaked on day 1, at 286 ± 170 pg / mL (p = 0.35 vs. untreated). Meanwhile, the drug concentration in animals treated with [P407 + cip + 3CPE(SDS)] and [P407 + cip] peaked at 35 ± 18 pg / mL (p = 0.99 vs. untreated), and 4 + 3 pg / ml (p = 0.99 vs. untreated) on day 1, respectively. By day 7, much of the ciprofloxacin in the middle ear had been cleared, and the MEF drug concentration from animals treated with [P407 + cip + 2% ML], [P407 + cip + 3CPE(SDS)], and [P407 + cip] was 30 + 14 pg / mL, 7 + 3 pg / mL, and 7 + 2 pg / mL, respectively.

[0151] Infected chinchilla bullae were retrieved after the 7-day course of treatment for histochemical staining and were analyzed under microscope and compared to healthy chinchilla bullae. FIG. 9A provides a representative microscope image of a sectioned tympanic membrane from a healthy chinchilla following hematoxylin & eosin (H&E) staining. Scale bar = 200 pm.

[0152] FIG. 9B provides a representative microscope image of a sectioned chinchilla tympanic membrane following infection with NTHi (day 0) and 7 days of no treatment (n=4) and H&E staining. The average tympanic membrane thickness in FIG. 9B was measured tobe 42 + 21 pm. The black arrow indicates regions of infiltrating leukocytes. Scale bar = 200 pm.

[0153] FIG. 9C provides a representative microscope image of a sectioned chinchilla tympanic membrane following infection with NTHi (day 0) and 7 days of treatment with P407 + cip (n=3) and H&E staining. The average tympanic membrane thickness in FIG. 9C was measured to be 101 ± 71 pm. Scale bar = 200 pm

[0154] FIG. 9D provides a representative microscope image of a sectioned chinchilla tympanic membrane following infection with NTHi (day 0) and 7 days of treatment with P407 + cip + 3CPE(SDS) (n=4) and H&E staining. The average tympanic membrane thickness in FIG. 9D was measured to be 36 ± 10 pm. Scale bar = 200 pm.

[0155] FIG. 9E provides a representative microscope image of a sectioned chinchilla tympanic membrane following infection with NTHi (day 0) and 7 days of treatment with P407 + cip + 2% methyl laurate (n=4) and H&E staining. The average tympanic membrane thickness in FIG. 9D was measured to be 18 + 5 pm. Scale bar = 200 pm.

[0156] FIGs. 10A-10E provide representative microscope images under a cross-sectional view. Referring to FIG. 10A, the TM thickness was measured to be 12 + 3 pm in a healthy chinchilla (n = 1), which, referring to FIG. 10B, was increased to 49 + 46 pm in untreated, infected chinchillas due to the inflammatory response (n = 4). Referring to FIGs. 10C, 10D, and 10E, after treatment with [P407 + cip], [P407 + cip + 3CPE(SDS)], and [P407 + cip + 2% ML], the tympanic membrane thickness was measured to be 42 + 21 pm, 101 + 71 pm, and 36 + 10 pm, respectively (n = 3, n = 4, n = 4, respectively).

[0157] Referring to FIGs. 9B-9E and 10B-10E, treatment with [P407 + cip], [P407 + cip + 3CPE(SDS)], or [P407 + cip + 2% ML] reduced the inflammatory signs but failed to bring the tympanic membranes to pristine conditions. Gram staining suggested the presence of clusters of bacteria in the middle ear or near the tympanic membranes in the groups that were untreated (FIGs. 9B & 10B), treated with [P407 + cip] (FIGs. 9C & 10C), or treated but uncured with [P407 + cip + 3CPE(SDS)] (FIGs. 9D & 10D). Such bacteria clusters were absent from the animals treated with [P407 + cip + 2% ML] (FIGs. 9E & 10E).Example 5: Compositions Comprising Methyl Laurate, Limonene, and Bupivacaine

[0158] SDS was previously used in a synergistic combination of CPE called 3CPE(SDS), consisting of 0.5% bupivacaine, 1% SDS, and 2% limonene (see Refs. 18, 33). However, compositions containing 18% P407, 3CPE(SDS), and 4% ciprofloxacin had limited success in treating otitis media in chinchillas (see Ref. 33). Not being bound by any particular theory,this poor efficacy is likely to the presence of SDS, which inhibits both the gelation and hydrogel homogeneity (see Refs. 8, 13, 14, 63). Consistent with these previous works, in this study, addition of 1% SDS to P407 compositions almost completely suppressed thermoresponsive gelation and the composition with 3CPE(SDS) suffered from a low gelation temperature, which made it difficult to administer onto tympanic membranes.

[0159] Based on the promising in vivo efficacy of the methyl laurate-containing hydrogel compositions, a hydrogel containing 18% w / v P407, 4% w / v ciprofloxacin, and 3CPE(ML) - a new CPE combination of 1% w / v ML, 2% w / v limonene, and 0.5% w / v bupivacaine (directly replacing SDS from 3CPE(SDS) with ML). This hydrogel demonstrated an 86% cure rate from day 1 to day 7 after treatment (n = 7). The median CFU counts in the MEF retrieved from the treated bullae showed a sharp decrease from 1.10 x 107 to 0 on day 1. The ciprofloxacin concentration in the MEF also peaked on day 1, reaching 305 ± 170 pg / ml. As treatment with [P407 + cip + 2% ML] and [P407 + cip + 3CPE(ML)] led to similar cure rates (83% and 86%, respectively), and similar CFU counts and ciprofloxacin content in the MEF, methyl laurate as the lone chemical permeation enhancer can be seen as an effective replacement to more complex combinations of chemical permeation enhancers.

[0160] Further, cytotoxicity testing indicates that methyl laurate has much lower cytotoxicity than SDS or 3CPE(ML) based on in vitro studies conducted using primary human adult fibroblast cells and PC 12, which is a pheochromocytoma cell line used in neurotoxicity testing. While P407 had minimal cytotoxicity, ciprofloxacin showed evident cytotoxicity at 4% concentration. Nonetheless, when these hydrogel compositions were assessed for biocompatibility in healthy chinchilla ears, the thickness of TMs treated with [P407 + cip], [P407 + cip + 3CPE(SDS)], and [P407 + cip + 2% ML], was measured to be 11 ± 5 pm, 31 + 4 pm, and 38 + 5 pm, respectively (n = 1). After 7 days of treatment, these hydrogel compositions only induced slight inflammation of the TM, likely due to the exfoliating effect of the surfactant and pseudo-surfactant.Example 6: DSC and Rheology of ML- and SDS-Containing Compositions

[0161] The effect of SDS and ML on P407 gelation was investigated by comparing the composition rheology, micellization thermodynamics, and hydrogel structure before and after the addition of SDS or ML. To match the in vitro and in vivo measurements, 18% (w / v) P407 was used unless otherwise stated. While P407 micellization and gelation processes have been extensively reported (see Refs. 32, 44-49), careful characterization at 18% (w / v) P407 servedas a means to compare various compositions containing different chemical permeation enhancers.

[0162] Referring to FIG. 11, in an aqueous solution of 18% (w / v) P407, the micellization transition was observed using differential scanning calorimetry (DSC), with polypropylene oxide) dehydration and micellization corresponding to a broad endothermic peak in the heat flow trace (see Refs. 32, 46, 51-54). Consistent with prior reports (see Refs. 55, 56), increases in temperature resulted in a many-order-of-magnitude increase in the dynamic moduli as the compositions underwent the solution-to-gel transition.

[0163] Referring to FIG. 12, micelle formation was also apparent in the 1-dimensional small-angle X-ray scattering (SAXS) trace at 25 °C (black) by the broad peak at approximately 0.035 A’1; q = 4TTX“1sin(0 / 2) is the magnitude of the scattering wave vector, where is the radiation wavelength and 9 is the scattering angle. Upon heating above about 27 °C, the appearance of sharp Bragg peaks in the SAXS traces at characteristic positions of q / q* = 1, (4 / 3), (8 / 3), (11 / 3), 2 (see Ref. 57), which correspond to the (111), (200), (220), (311), and (222) crystallographic planes, respectively, for micelles ordered into a facecentered cubic (FCC) packing. The radius of the micelles, Rmic, was estimated as half of the nearest-neighbor distance between micelles on the FCC lattice. For [P407], Rmic is 109 A at 35 °C. This micelle size closely matched the hydrodynamic radius, Rh, of micelles in a 1% (w / v) P407 solution at 37 °C measured via dynamic light scattering (DLS) and is consistent with P407 micelle sizes reported previously (see Refs. 32, 48, 58).

[0164] Referring to FIG. 13 A, rheology data showed similar gelation temperatures and gel moduli for formulations containing 18% P407 and 18% P407+2% ML, indicating that the addition of 2% methyl laurate does not dramatically change the formation of P407 hydrogels.

[0165] On the other hand, 18% P407 solutions with 2% SDS did not exhibit a temperature-dependent rheological transition, showing the disruptive effect of SDS on hydrogel formation. Referring to FIG. 12, the addition of 2% (w / v) SDS to an 18% (w / v) P407 solution, i.e., [P407 + 2% w / v SDS], eliminated gelation, resulting in a low-modulus liquid across the examined temperature range. Based on the data and experiments described herein, this disruption to gelation, observed for a range of P407 and SDS concentrations, stems from SDS-P407 interactions that impede temperature-dependent micellization (see Refs. 8, 59). Indeed, the absence of P407 micellization was confirmed via DSC and SAXS, indicating that P407 micellization can be inhibited entirely above a critical SDS concentration (> 2 mM SDS in an aqueous solution containing 1% (w / w) P407) (see Refs. 8, 63).

[0166] Referring to FIG. 13B, rheology data show that solutions containing P407, P407+cip, P407+2% ML, and P407+cip+2% ML exhibit similar gelation temperatures and gel moduli. The traces show that addition of 4% cip, 2% ML, or 4% cip + 2% ML has no significant impact on gelation temperature or gel modulus across solutions containing P407.

[0167] Referring to FIG. 14, no endothermic peak was observed in the DSC trace for P407 + 2% w / v SDS. DSC of P407 + 2% ML showed that ML addition only slightly decreased the micellization and gelation temperatures.Example 7: Small Angle X-ray Scattering of ML- and SDS-Containing Compositions

[0168] Synchrotron small-angle X-ray scattering (SAXS) measurements were conducted at Sector 5-ID-D of the Advanced Photon Source (APS) at Argonne National Lab.Measurements were conducted using a wavelength of 0.793 A, allowing for an accessible q- range from 0.002 to 4.4 A-l across three detectors. Data were truncated to highlight features of interest between 0.02 and 0.1 A’1. Samples were loaded into 1.5-mm quartz capillaries within a custom multi-capillary temperature stage and scanned every 5 °C from 5 °C to 50 °C following a 10-minute equilibration period at each temperature. Select samples containing ML and ciprofloxacin hydrochloride were scanned at 37 °C. Each scan used a 1 second exposure time and every sample was scanned in three positions vertically along the capillary. The 2D patterns were visualized using DataSqueeze80 and azimuthally integrated to yield ID traces. Ordered phases were identified based on the position of Bragg peaks within the ID traces.

[0169] Referring to FIG. 15 A, no distinguishable features were present in the SAXS trace at 35 °C (near body temperature) for P407 + 2% w / v SDS. This indicates a lack of a well- defined or ordered population of micelle for 18% P407 solutions with 2% SDS.

[0170] The SAXS traces of P407 and P407 + 2% w / v ML confirmed that both gels at 35 °C contained FCC -packed micelles with virtually identical sizes, indicating that 2% ML has no appreciable impact on P407 gel formation.

[0171] Referring to FIG. 15B, SAXS traces at 35 °C showed unchanged micelle radius, Rmic, with the addition of either 4% w / v ciprofloxacin or 2% w / v ML to an 18% w / v P407 solution. Specifically, a solution containing 18% P407 has a micelle radius, Rmic, of 109 A, and addition of either 4% cip or 2% methyl laurate (“ML”) had no appreciable impact on micelle radius, with measured Rmic = 110 A in both cases. The addition of both 4% cip and 2% ML dramatically increases the lattice size and corresponding Rmic to 143 A. All compositions pack onto an Face-Center Cubic lattice as indicated by black triangles. Two-dimensional patterns for P407 + cip and P407 + cip + ML compositions show differences in the intensity and textures of the peaks.

[0172] Referring to FIG. 15C, Rmic is plotted as a function of the ML concentration in formulations containing 18% w / v P407 and 4% w / v ciprofloxacin, where Rmic was determined via SAXS. Dashed line indicates a 1:1 molar ratio of CIP:ML.Example 8: Dynamic Light Scattering & Optical Characterization of P407 / ML P407 / SDS Compositions

[0173] The structure of P407, P407 / ML and P407 / SDS solutions was further examined by performing dynamic light scattering (DLS) on compositions containing [P407 + 2% w / v SDS] (diluted 10-fold) and [P407 +0.1% w / v ML],

[0174] Samples were prepared with a P407 concentration of 1% w / v. The ratio of P407 to small molecules was kept constant between the concentrated (18% P407) and dilute samples. All components were dissolved in HPLC-grade water at 4 °C. Samples were then heated to 37 °C to allow for micelle formation prior to being passed through a 0.22- pm hydrophilic polypropylene (GHP) filter. The filtered solutions were loaded into glass tubes for measurements.

[0175] Multi-angle DLS was performed on a Brookhaven BL200SM instrument with a 637 nm laser. Throughout the measurements, samples were submerged in a circulating decalin bath maintained at 37 °C. Autocorrelation functions were collected for 5 minutes over a range of 0.5 ps to 10 ms at 60°, 75°, 90°, 105°, and 120°. Regularized positive exponential sum (REPES) analysis was used to determine that all data could be described by a single relaxation mode. Hydrodynamic radii were determined by fitting the data at each angle to a second cumulant expansion. For each sample, there was a strong linear relationship between the first cumulant versus scattering angle squared, indicating a diffusive process. The slope of this line corresponds to the mutual diffusion coefficient (Dm), which in these dilute solutions is equivalent to the tracer diffusion coefficient (Dt). The tracer diffusion coefficient can be related to the hydrodynamic radius using the Stokes-Einstein relation.

[0176] Referring to FIG. 16, DLS revealed a highly dispersed population of aggregates with an average hydrodynamic radius, Rh of 47 A. This measured hydrodynamic radius is consistent with that of an SDS micelle stabilized by a single P407 chain. Thus, as P407 micellization is a critical precursor to gelation, SDS incorporation prevents the solution-to-gel transition of the P407 formulation by disrupting P407 micellization.

[0177] Referring to FIG. 16, DLS measurements on dilute solutions of 1% w / v P407 with 0.1% w / v ML (matching that of the DLS measurements performed on [P407 + SDS]) showed that the hydrodynamic radius of micelles in dilute solutions [P407 + 0.1% ML] was nearly identical to that of 1% w / v P407, suggesting negligible ML incorporation into the P407 micelles, which is consistent with the SAXS results.

[0178] Optical microscopy was used to visualize the size of ML droplets within hydrogels containing 18% P407 with 2% ML. Measurements were conducted on an Olympus BX53 microscope. Samples were preheated to 37 °C before being transferred to a glass microscope slide. Samples were then placed into a Linkam T95 temperature controller and imaged at 37 °C.

[0179] As seen in FIG. 17A, the addition of P407 (18% w / v) to water results in a clear aqueous solution. Unlike SDS, which is readily soluble in water, ML has a very low aqueous solubility (< 0.008 g / L at 25 °C57). Referring to FIG. 17B, the addition of P407 (18% w / v) to aqueous solutions of 2% w / v ML, i.e., [P407 + 2% ML], appeared to stabilize ML droplets, forming a uniformly semi-cloudy emulsion. The resulting gels were imaged via optical microscopy at 37 °C, FIG. 17B, inset. These images clearly show ML droplets with a droplet diameter on the order of 10 pm.Example 9: Cytotoxicity Testing

[0180] Healthy chinchilla tympanic membranes were also assessed for tissue toxicity by treating with [P407 + cip], [P407 + cip + 3CPE(SDS)], and [P407 + cip + 2% ML] for 7 days. Following treatment with [P407 + cip], [P407 + cip + 3CPE(SDS)], and [P407 + cip + 2% ML] for 7 days, healthy chinchilla tympanic membranes exhibited only slight inflammations, showing a thickness of 11 + 5 pm, 38 + 9 pm, and 38 + 5 pm, respectively (n = 1).

[0181] The slight inflammations were likely as a result of the exfoliating effect of the surfactant and pseudo-surfactant, and no other histological abnormalities were witnessed.

[0182] Cytotoxicity was also assessed in vitro using primary human adult fibroblast cells and PC 12 (a pheochromocytoma cell line used in neurotoxicity testing). Adult primary dermal fibroblast cells (hFbs, ATCC PCS-201-012) were maintained in fibroblast basal medium (ATCC PCS-201-030) supplemented with low-serum growth kit (ATCC PCS-201- 041) and 1% penicillin / streptomycin (Gibco 15-140-122). PC-12 cells (ATCC CRL-1721.1), isolated from pheochromocytoma, were maintained in F-12K medium (Gibco 21-127-022) supplemented with 2.5% fetal bovine serum (Gibco 16-000-044), 15% horse serum (Gibco26-050-088) and 1% penicillin / streptomycin (Gibco 15-140-122). All cell cultures were maintained in an incubator kept at 37°C and 5% CO2.

[0183] For cytotoxicity testing, hFbs and PC- 12 cells were seeded into 12- well plates at a cell density of 80,000 cells / well and incubated overnight prior to being treated with the various formulations. Small molecule compounds and CPEs (without P407) were directly dissolved in media, or dissolved in media with 1% v / v dimethyl sulfoxide (DMSO, Coming®) in the case of ML to improve its solubility. After one day of culture, cell media were replaced with 1 mL fresh media containing the tested compounds. For formulations containing P407, 200 pL of the formulation was placed into a pre-warmed sterile insert (12-mm Transwell® insert with 0.4-pm pore polyester membrane, Corning® 3460) and the insert was placed in a well with the cells and 1 mL fresh media. After 24 h of treatment, cell viability was measured with the WST-8 cell proliferation assay kit (Cayman Chemical 10010199) and the LIVE / DEAD™ viability / cytotoxicity kit (Invitrogen L3224). In brief, WST-8 mixture solution was freshly prepared and added to each well to a final concentration of 10% of the media volume. After 2 - 4 hours of incubation at 37°C, the media were collected from each well, centrifuged, and measured for absorbance at 450 nm in a plate reader. For live / dead staining, cells were incubated with calcein-AM (1 mM) and ethidium homodimer (2 mM) for 15 - 30 minutes at 37 °C and then imaged with a fluorescent microscope (Axiovert, Zeiss). Cell viability was calculated as (live cells) / (live cells + dead cells) * 100%. ML demonstrated much-improved biocompatibility compared to SDS or 3CPE(ML). Meanwhile, the P407 hydrogel had minimal cytotoxicity, but ciprofloxacin showed evident cytotoxicity at 4% w / v.REFERENCES1. Karande, P.; Jain, A.; Ergun, K.; Kispersky, V.; Mitragotri, S., Proc Natl Acad Sci U S A 2005, 102 (13), 4688-93. DOI 10.1073 / pnas.0501176102.2. Pham, Q. D.; Bjorklund, S.; Engblom, J.; Topgaard, D.; Sparr, E., J Control Release 2016, 232, 175-87. DOI 10.1016 / j.jconrel.2016.04.030.3. Hassan, N.; Ahad, A.; Ali, M.; Ali, J., Expert Opin Drug Deliv 2010, 7 (1), 97-112. DOI 10.1517 / 17425240903338758.4. Maher, S.; Brayden, D. J., Adv Drug Deliv Rev 2021, 177, 113925. DOI 10.1016 / j.addr.202L 113925.5. Williams, A. C.; Barry, B. W., Adv Drug Deliv Rev 2004, 56 (5), 603-18. DOI 10.1016 / j.addr.2003.10.025.6. Ivanova, R.; Alexandridis, P.; Lindman, B., Colloids and Surfaces A: Physicochemical and Engineering Aspects 2001, 183-185, 41-53. DOI 10.1016 / S0927-7757(01)00538-6.Zhang, K.; Lindman, B.; Coppola, L., Langmuir 1995, 11 (2), 538-542. DOI 10.1021 / la00002a029. Hecht, E.; Mortensen, K.; Gradzielski, M.; Hoffmann, H., The Journal of Physical Chemistry 1995, 99 (13), 4866-4874. DOI 10.1021 / jl00013a068. Bharatiya, B.; Ghosh, G.; Bahadur, P.; Mata, J., Journal of Dispersion Science and Technology 2008, 29 (5), 696-701. DOI 10.1080 / 01932690701751876. Abd-El Hafeez, S. I.; Eleraky, N. E.; Hafez, E.; Abouelmagd, S. A., Sci Rep 2022, 12 (1), 5737. DOI 10.1038 / s41598-022-09384-6. Li, H.; Wu, W.; Hao, X.; Wang, S.; You, M.; Han, X.; Zhao, Q.; Xing, B„ Environ Pollut 2018, 243 (Pt A), 206-217. DOI 10.1016 / j.envpol.2018.08.059. Ahsan, S. M. A.; Amin, M. R.; Mahbub, S.; Molla, M. R.; Aktar, S.; Rub, M. A.; Hoque, M. A.; Arshad, M. N.; Khan, M. A., Chinese Journal of Chemical Engineering 2020, 28 (1), 216-223. DOI 10.1016 / j.cjche.2019.03.019. Banipal, T. S.; Kaur, R.; Banipal, P. K., Journal of Molecular Liquids 2018, 255, 113- 121. DOI 10.1016 / j. molliq.2018.01.089. Khan, A. M.; Shah, S. S., Journal of Dispersion Science and Technology 2009, 30 (9), 1247-1254. DOI 10.1080 / 01932690902735058. Whitehead, K.; Mitragotri, S., Pharm Res 2008, 25 (6), 1412-9. DOI 10.1007 / s 11095- 008-9542-2. Mittal, R.; Parrish, J. M.; Soni, M.; Mittal, J.; Mathee, K., J Med Microbiol 2018, 67 (10), 1417-1425. DOI 10.1099 / jmm.0.000810. Thomas, J. P.; Berner, R.; Zahnert, T.; Dazert, S., Dtsch Arztebl Int 2014, 111 (9), 151-9; quiz 160. DOI 10.3238 / arztebl.2014.0151. Khoo, X.; Simons, E. J.; Chiang, H. H.; Hickey, J. M.; Sabharwal, V.; Pelton, S. I.; Rosowski, J. J.; Langer, R.; Kohane, D. S., Biomaterials 2013, 34 (4), 1281-8. DOI 10.1016 / j. biomaterials.2012.10.025. Zhang, Z.; Li, X.; Zhang, W.; Kohane, D. S., Adv Funct Mater 2021, 31 (44). DOI 10.1002 / adfm.202008701. Axelsson, M„ BMC Psychol 2013, 1 (1), 24. DOI 10.1186 / 2050-7283-1-24. Zielnik- Jurkiewicz, B.; Bielicka, A., Int J Pediatr Otorhinolaryngol 2015, 79 (12), 2129- 33. DOI 10.1016 / j. ijporl.2015.09.030. Anderson, R. M„ Nat Med 1999, 5 (2), 147-9. DOI 10.1038 / 5507. Menon, G. K.; Cleary, G. W.; Lane, M. E„ Int J Pharm 2012, 435 (1), 3-9. DOI 10.1016 / j. ijpharm.2012.06.005.Volandri, G.; Di Puccio, F.; Forte, P.; Carmignani, C., J Biomech 2011, 44 (7), 1219-36. DOI 10.1016 / j.jbiomech.2010.12.023. Kuypers, L. C.; Decraemer, W. F.; Dirckx, J. J., Otol Neurotol 2006, 27 (2), 256-64. DOI 10.1097 / 01.mao.0000187044.73791.92. Liu, X.; Li, M.; Smyth, H.; Zhang, F„ Drug Dev Ind Pharm 2018, 44 (9), 1395-1408.DOI 10.1080 / 03639045.2018.1464022. Roland, P. S.; Wall, M., Expert Opin Pharmacother 2008, 9 (17), 3129-35. DOI 10.1517 / 14656560802489262. FDA Ciprodex: Highlights of prescribing information. https: / / www.accessdata.fda.gov / drugsatfda_docs / label / 2019 / 021537s0171bl.pdf. FDA Cetraxal: Highlights of prescribing information. https: / / www.accessdata.fda.gov / drugsatfda_docs / label / 2009 / 0219181bl.pdf. Yang, R.; Okonkwo, O. S.; Zurakowski, D.; Kohane, D. S., J Control Release 2018, 289, 94-101. DOI 10.1016 / j.jconrel.2018.06.019. Karande, P.; Jain, A.; Mitragotri, S., J Control Release 2006, 115 (1), 85-93. DOI 10.1016 / j.jconrel.2006.07.001. White, J. M.; Calabrese, M. A., Colloids Surf A Physicochem Eng Asp 2022, 638. DOI 10.1016 / j.colsurfa.202L 128246. Yang, R.; Sabharwal, V.; Okonkwo, O. S.; Shlykova, N.; Tong, R.; Lin, L. Y.; Wang, W.; Guo, S.; Rosowski, J. J.; Pelton, S. I.; Kohane, D. S., Sci Transl Med 2016, 8 (356), 356ral20. DOI 10.1126 / scitranslmed.aaf4363. Yang, R.; Sabharwal, V.; Shlykova, N.; Okonkwo, O. S.; Pelton, S. I.; Kohane, D. S., JCI Insight 2018, 3 (19). DOI 10.1172 / jci.insight.123415. Zhang, Y.; Inal, S.; Hsia, C.-Y.; Ferro, M.; Ferro, M.; Daniel, S.; Owens, R. M., Advanced Functional Materials 2016, 26 (40), 7304-7313. DOI 10.1002 / adfm.201602123. Bint, E. N. S. F.; Su, H.; Liu, H. Y.; Manzer, Z. A.; Chao, Z.; Roy, A.; Pappa, A. M.; Salleo, A.; Owens, R. M.; Daniel, S., ACS Appl Bio Mater 2021, 4 (11), 7942-7950. DOI 10.1021 / acsabm.lc00878. Tang, H.; Mitragotri, S.; Blankschtein, D.; Langer, R., J Pharm Sci 2001, 90 (5), 545-68. DOI 10.1002 / 1520-6017(200105)90:5<545::aid-jpsl012>3.0.co;2-h. van der Veen, J. N.; Kennelly, J. P.; Wan, S.; Vance, J. E.; Vance, D. E.; Jacobs, R. L., Biochim Biophys Acta Biomembr 2017, 1859 (9 Pt B), 1558-1572. DOI10.1016 / j.bbamem.2017.04.006.Alberts, B.; Johnson, A.; Lewis, J.; Raff, M.; Roberts, K.; Walter, P., Molecular Biology of the Cell. 4 ed.; Garland Science: New York, 2002. Piggot, T. J.; Pineiro, A.; Khalid, S., J Chem Theory Comput 2012, 8 (11), 4593-609. DOI 10.1021 / ct3003157. Apicella, M. A., J Infect Dis 2009, 199 (6), 774-5. DOI 10.1086 / 597043. Bakaletz, L. O., Expert Rev Vaccines 2009, 8 (8), 1063-82. DOI 10.1586 / erv.09.63. Wang, X.; Fernandez, R.; Tsivkovskaia, N.; Harrop- Jones, A.; Hou, H. J.; Dellamary, L.; Dolan, D. F.; Altschuler, R. A.; EeBel, C.; Piu, F., Otol Neurotol 2014, 35 (3), 459-69. DOI 10.1097 / MA0.0000000000000261. Ruel-Gariepy, E.; Eeroux, J. C., Eur J Pharm Biopharm 2004, 58 (2), 409-26. DOI 10.1016 / j.ejpb.2004.03.019. Mortensen, K.; Brown, W., Macromolecules 1993, 26 (16), 4128-4153. Wanka, G.; Hoffmann, H.; Ulbricht, W., Macromolecules 1994, 27 (15), 4145-4159. DOI 10.1021 / ma00093a016. Parekh, P.; Dey, J.; Kumar, S.; Nath, S.; Ganguly, R.; Aswal, V. K.; Bahadur, P., Colloids Surf B Biointerfaces 2014, 114, 386-91. DOI 10.1016 / j.colsurfb.2013.10.030. Basak, R.; Bandyopadhyay, R., Langmuir 2013, 29 (13), 4350-6. DOI 10.1021 / la304836e. Alexandridis, P.; Athanassiou, V.; Fukuda, S.; Hatton, T. A., Langmuir 1994, 10 (8), 2604-2612. DOI 10.1021 / la00020a019. Cabana, A.; Ait-Kadi, A.; Juhasz, J., J Colloid Interface Sci 1997, 190 (2), 307-12. DOI 10.1006 / jcis.1997.4880. Alexandridis, P.; Hatton, T. A., Colloids Surf A Physicochem Eng Asp 1995, 96 (1-2), 1- 46. DOI 10.1016 / 0927-7757(94)03028-X. Chowdhry, B. Z.; Snowden, M. J.; Leharne, S. A., European Polymer Journal 1999, 35 (2), 273-278. DOI 10.1016 / S0014-3057(98)00129-3. Artzner, F.; Geiger, S.; Olivier, A.; Allais, C.; Finet, S.; Agnely, F., Langmuir 2007, 23 (9), 5085-92. DOI 10.1021 / la062622p. Beezer, A. E.; Loh, W.; Mitchell, J. C.; Royall, P. G.; Smith, D. O.; Tute, M. S.; Armstrong, J. K.; Chowdhry, B. Z.; Leharne, S. A., Langmuir 1994, 10 (11), 4001-4005. DOI 10.1021 / la00023a017. Liu, S.; Bao, H.; Li, L., European Polymer Journal 2015, 71, 423-439. DOI 10.1016 / j.eurpolymj.2015.08.016.Suman, K.; Sourav, S.; Joshi, Y. M., Physics of Fluids 2021, 33 (7), 073610. DOI 10.1063 / 5.0057090. Hamley, I. W.; Castelletto, V., Progress in Polymer Science 2004, 29 (9), 909-948. DOI 10.1016 / j.progpolymsci.2004.06.001. Attwood, D.; Collett, J. H.; Tait, C. J., International Journal of Pharmaceutics 1985, 26 (1), 25-33. DOI 10.1016 / 0378-5173(85)90197-8. Kancharla, S.; Bedrov, D.; Tsianou, M.; Alexandridis, P., J Colloid Interface Sci 2022, 609, 456-468. DOI 10.1016 / j.jcis.2021.10.176. Li, Y.; Xu, R.; Bloor, D. M.; Holzwarth, J. F.; Wyn-Jones, E., Langmuir 2000, 16 (26), 10515-10520. DOI 10.1021 / la000899y. Li, Y.; Xu, R.; Couderc, S.; Bloor, M.; Wyn-Jones, E.; Holzwarth, J. E., Langmuir 2001, 17 (1), 183-188. DOI 10.1021 / la001075j. Kancharla, S.; Zoyhofski, N. A.; Bufalini, L.; Chatelais, B. F.; Alexandridis, P., Polymers (Basel) 2020, 12 (8). DOI 10.3390 / polyml2081831. Hecht, E.; Hoffmann, H., Langmuir 1994, 10 (1), 86-91. Book, C. Methyl laurate: CAS DataBase List. https : / / www .chemicalbook.com / ChemicalProductProperty_EN_CB 6274029.htm. PubChem Ciprofloxacin (Compound). https: / / pubchem.ncbi.nlm.nih.gov / compound / Ciprofloxacin. Edmunds, A. L„ P T 2017, 42 (5), 307-311. PubChem Ammonium Chloride. https: / / pubchem.ncbi.nlm.nih.gov / compound / Ammonium-Chloride. Miro, N.; The Spanish ENT study group, Otolaryngol Head Neck Surg 2000, 123 (5), 617-23. DOI 10.1067 / mhn.2000.107888. FDA Otiprio: Highlights of prescribing information. https: / / www.accessdata.fda.gov / drugsatfda_docs / label / 2018 / 207986s0021bl.pdf. Grillo, I.; Morfin, I.; Prevost, S., Langmuir 2018, 34 (44), 13395-13408. DOI 10.1021 / acs.langmuir.8b03050. Nagarajan, R., Colloids and Surfaces B: Biointerfaces 1999, 16 (1), 55-72. DOI 10.1016 / S0927-7765(99)00061-2. Chrzanowska, A.; Olejarz, W.; Kubiak-Tomaszewska, G.; Ciechanowicz, A. K.; Struga, M., Cancers (Basel) 2022, 14 (2). DOI 10.3390 / cancers 14020409. Moghadam, S. H.; Saliaj, E.; Wettig, S. D.; Dong, C.; Ivanova, M. V.; Huzil, J. T.; Foldvari, M„ Mol Pharm 2013, 10 (6), 2248-60. DOI 10.1021 / mp300441c.Ananthapadmanabhan, K. P.; Yu, K.; Meyers, C. L.; Aronson, M. P., Journal of the society of cosmetic chemists 1996, 47, 185-200. Morris, S. A. V.; Ananthapadmanabhan, K. P.; Kasting, G. B., J Pharm Sci 2019, 108 (11), 3640-3648. DOI 10.1016 / j.xphs.2019.06.030. Haque, T.; Talukder, M. M. U., Adv Pharm Bull 2018, 8 (2), 169-179. DOI 10.15171 / apb.2018.021. Daily Med Drug label information: Fentanyl system - fentanyl patch. https: / / dailymed.nlm.nih.gov / dailymed / druglnfo. cfm?setid=242759ef-cb6d-4e3e-9f8d- 5e31efalf289. Daily Med Drug label information: Androderm - testosterone patch. https: / / dailymed.nlm.nih.gov / dailymed / druglnfo. cfm?setid=e58a5328-fdd9-40cb-al9f- 8ed798989b9c. Heiney, P. A., Int. Union Crystallogr 2005, 32, 9-11. Schindelin, J.; Arganda-Carreras, I.; Frise, E.; Kaynig, V.; Longair, M.; Pietzsch, T.; Preibisch, S.; Rueden, C.; Saalfeld, S.; Schmid, B.; Tinevez, J. Y.; White, D. J.;Hartenstein, V.; Eliceiri, K.; Tomancak, P.; Cardona, A., Nat Methods 2012, 9 (7), 676- 82. DOI 10.1038 / nmeth.2019.

Claims

CLAIMSWhat is Claimed is:

1. A composition comprising: a therapeutic compound having a molecular weight of about 200 g / mol to about 1,000 g / mol that is at least one of:(i) ionized at pH 3 to 8;(ii) contains a Hydrogen-bond donor functional group;(iii) contains a Hydrogen-bond acceptor functional group;(iv) or a combination thereof; a first compound comprising a fatty acid methyl ester having a Ce to Cis n-alkyl or branched alkyl chain; a second compound comprising a hydrophilic non-ionic surfactant; and water, wherein the composition has a pH of 3 to 8.

2. The composition of claim 1, wherein the hydrophilic non-ionic surfactant has the structure of formula I:wherein a is an integer from about 50 to about 150, and b is an integer from about 40 to about 70.

3. The composition of claim 2, wherein a is an integer from about 75 to about 125, and b is an integer from about 50 to about 60.

4. The composition of claim 3, wherein a is about 155 and b is about 100.

5. The composition of any of claims 1-4, wherein the second compound is present in a concentration of about 10% w / v to about 25% w / v.

6. The composition of any of claims 1-4, wherein the second compound is present in a concentration of about 15% w / v to about 25% w / v.

7. The composition of any of claims 1-6, wherein the first compound is methyl laurate.

8. The composition of any of claims 1-7, wherein the first compound is present in a concentration of about 0.5% w / v to about 5% w / v.

9. The composition of any of claims 1-7, wherein the first compound is present in a concentration of about 1% w / v to about 4% w / v.

10. The composition of any of claims 1-7, wherein the first compound is present in a concentration of about 2% w / v.

11. The composition of any of claims 1-10, wherein the therapeutic compound is a quinolone antibiotic is present in a concentration of about 0.1% w / v to about 10% w / v.

12. The composition of any of claims 1-10, wherein the therapeutic compound is present in a concentration of about 1% w / v to about 8% w / v.

13. The composition of any of claims 1-10, wherein the therapeutic compound is present in a concentration of about 2% w / v to about 6% w / v.

14. The composition of any of claims 1-13, wherein the therapeutic compound is a quinolone antibiotic.

15. The composition of any of claims 1-13, wherein the therapeutic compound is a quinolone antibiotic selected from the group consisting of: ciprofloxacin, garenoxacin, gatifloxacin, gemifloxacin, levofloxacin, moxifloxacin, and combinations thereof.

16. The composition of any of claims 1-13, wherein the therapeutic compound is ciprofloxacin.

17. A composition comprising: a therapeutic compound comprising a quinolone antibiotic selected from the group consisting of: ciprofloxacin, garenoxacin, gatifloxacin, gemifloxacin, levofloxacin, moxifloxacin, and combinations thereof, present in a concentration of about 2% w / v to about 6% w / v; a first compound comprising methyl laurate, in a concentration of about 1% w / v to about 4% w / v; a second compound comprising a hydrophilic non-ionic surfactant having the structure of Formula I:wherein a is an integer from about 75 to about 125, and b is an integer from about 50 to about 60, and wherein the hydrophilic non-ionic surfactant is present in a concentration of about 10% w / v to about 25% w / v; and water, wherein the composition has a pH of 3 to 8.

18. The composition of any of claims 1-17, wherein the first compound further comprises a permeation enhancer.

19. The composition of any of claim 18, wherein the permeation enhancer is selected from: limonene, bupivacaine, and combinations thereof.

20. The composition of any of claims 1 to 19, further comprising a Ci to Cs alcohol.

21. A composition to facilitate administration of a therapeutic compound, the composition comprising: a therapeutic compound having a molecular weight of about 200 g / mol to about 1,000 g / mol that is at least one of:(i) ionized at pH 3 to 8;(ii) contains a Hydrogen-bond donor functional group; or(iii) contains a Hydrogen-bond acceptor functional group; a first compound comprising a fatty acid methyl ester having a Ci> to Cis n-alkyl or branched alkyl chain; a second compound comprising a hydrophilic non-ionic surfactant; and water, wherein the composition has a pH of 3 to 8.

22. The composition of claim 21, wherein the permeation enhancer consists essentially of a fatty acid methyl ester having a Ci> to Cis n-alkyl or branched alkyl chain.

23. The composition of any of claims 21 to 22, wherein the first compound consists essentially of methyl laurate.

24. The composition of claim 21, further comprising limonene or bupivacaine, or a combination thereof.

25. A composition for delivering a therapeutic compound to a patient comprising: a therapeutic compound having a molecular weight of about 200 g / mol to about 1,000 g / mol that is at least one of:(i) ionized at pH 3 to 8;(ii) contains a Hydrogen-bond donor functional group; or(iii) contains a Hydrogen-bond acceptor functional group; a first compound comprising one or more ester groups and one or more optionally substituted Ci> to Cis chains, wherein the first compound and therapeutic compound interact form a pseudo-surfactant assembly; a second compound comprising a non-ionic surfactant, a neutral surfactant, a hydrogel precursor, or a combination thereof that forms a micelle, liposome, or vesicle with water, wherein the pseudo-surfactant assembly is incorporated into the micelle, liposome, or vesicle; and water, wherein the composition has a pH of 3 to 8.

26. The composition of claim 25, wherein the therapeutic compound is 0.005% w / v to 20% w / v, the first compound is 0.005% w / v to 20% w / v, the second compound is 12% w / v to 50% w / v.

27. The composition of claim 25, wherein the composition comprises 0.005% w / v to 10% w / v of the therapeutic compound, 0.005% w / v to 10% w / v of the first compound, 12% w / v to 50% w / v of the second compound, and 30% w / v to 87% w / v of water.

28. The composition of any of claims 25 to 27, wherein the molar ratio of the therapeutic compound and first compound is selected from about 1:2 to about 2:1, or about 1:1.

29. The composition of any one of the claims 25 to 28, wherein the therapeutic compound is selected from a quinolone antibiotic, a tetracycline antibiotic, a macrolide antibiotic, an aminoglycoside, a steroid, or a derivative thereof.

30. The composition of any one of the claims 25 to 29, wherein the first compound is selected from an ester, a diester, or an oligo-ester.

31. The composition of any one of the claims 25 to 30, wherein the first compound is a fatty acid ester having a C<> to Cis n-alkyl or branched alkyl chain and a methyl, ethyl, propyl, isopropyl, or butyl ester group.

32. The composition of any one of the claims 25 to 31, wherein the second compound is selected from a polysorbate, sodium lauryl sulfate, poloxamer, polyoxyl 40 hydrogenated castor oil, lauroyl polyoxyl-32 glycerides, mannide monooleate, and / or propylene glycol monocaprylate.

33. The composition of any one of the claims 25 to 32, wherein the second compound is selected from a poloxamer or a derivative thereof, a reverse poloxamer or a derivative thereof, a polyethylene glycol polymer, and combinations thereof.

34. The composition of any one of the claims 25 to 33, wherein the second compound is selected from P407, P188, P338, MAKON 17R2, MAKON 17R4, poloxamer / pluronic diacrylate, poloxamer dimethacrylate, PEGDA, PEGMA, PLGA- PEG-PLGA, PEG-PCL-PEG, or a combination thereof.

35. The composition of any one of the claims 25 to 34, wherein the second compound is a thermoresponsive polymer, a thermoresponsive block copolymer, or a combination thereof.

36. The composition of any one of the claims 25 to 35, wherein the composition is thermosensitive with a transition from a liquid at a first temperature to a hydrogel at a second temperature.

37. The composition of any one of the claims 25 to 36, wherein the composition is a stable hydrogel in a temperature of about 20 °C to about 40 °C.

38. The composition of any one of the claims 25 to 37, wherein the composition has a solgel transition temperature in a range of about 4 °C to about 35 °C.

39. The composition of any one of the claims 25 to 38, further comprising one or more additives.

40. The composition of the claim 39, wherein the one or more additives is selected from a terpene, a terpenoid, an alcohol, an alkanols, a phenol, a sulfoxide, a glycol, a fatty acid a fatty acid derivative, or a combination thereof.

41. The composition of any one of the claims 25 to 40, further comprising one or more additional therapeutic compounds.

42. The composition of any one of the claims 25 to 41, wherein the first compound has a solubility of less than 0.1 g / L in water at 20 °C.

43. A method of administering a therapeutically effective amount of the composition of any of claims 1 to 42 to a subject in need thereof.

44. The method of claim 43, wherein the subject suffers from otitis media.

Citation Information

Patent Citations

  • Pulmonary delivery of a fluoroquinolone

    US20150374685A1

  • Sterilization of ciprofloxacin composition

    US20160000948A1

  • Compositions with permeation enhancers for drug delivery

    US20220040309A1

  • PHARMACEUTICAL CARRIERS CAPABLE OF pH DEPENDENT RECONSTITUTION AND- METHODS FOR MAKING AND USING SAME

    WO2021195319A1